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Extracellular vesicles (EVs) are released into blood from multiple organs and carry 
molecular cargo that facilitates inter-organ communication and an integrated response to 
physiological and pathological stimuli.  Interrogation of the protein cargo of EVs is 
currently limited by the absence of optimal and reproducible approaches for purifying 
plasma EVs that are suitable for downstream proteomic analyses. We describe a size 
exclusion chromatography (SEC)-based method to purify EVs from platelet poor plasma 
(PPP) for proteomics profiling via high-resolution mass spectrometry (SEC-MS).  The 
SEC-MS method identified more proteins with higher precision compared to several 
conventional EV isolation approaches.  We applied the SEC-MS method to identify the 
unique proteomic signatures of EVs released from platelets, adipocytes, muscle cells, and 
hepatocytes, with the goal of identifying tissue-specific EV markers.  Further, we applied 
the SEC-MS approach to evaluate the effects of endurance and resistance exercise on EV 
proteomic cargo in human plasma.   
A prerequisite to studying the role of EVs in metabolic disorders such as type 2 
diabetes is an in-depth understanding of the molecular mechanisms involved in 
dysregulation of insulin sensitive tissues such as skeletal muscle. In line with this, we 
utilized a multi-omics approach to characterize mechanisms underpinning exercise 
resistance in obese individuals. In this study we characterized the difference in the response 
to acute exercise between healthy subjects and individuals with chronic inflammation using 





pathways, including glycogen synthesis, myogenesis and AMPK signaling in obese 
individuals.   
Finally, we utilized the biomarker potential of SEC-MS to identify differences in 
protein abundance and composition in EVs isolated from individuals with the 
hematological malignancy multiple myeloma (MM) and its precursor disease multiple 
myeloma of undetermined significance (MGUS). This analysis found that CD71 was 
upregulated in small and large EVs in individuals with MM relative to MGUS, suggesting 
that iron utilization and homeostasis in the tumor micro environment may play a role in 
disease progression. Additionally, CD40 was upregulated in individuals with standard 
cytogenetik risk MM relative to MGUS but was not identified in individuals with high risk 
MM suggesting that adaptive immune function is correlated to cytogenetic risk. These 
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Chapter 1  
INTRODUCTION 
 
Integrated physiology relies on proper communication between different tissues, 
and interest in extracellular vesicles (EVs) has grown rapidly in recent years, owing to their 
role in cell-to-cell communication (Colombo et al., 2014; Guay and Regazzi, 2017; van 
Niel et al., 2018). EVs are a diverse group of membrane vesicles consisting of two major 
categories, exosomes and microvesicles. Exosomes range in size from of ~40 to 160nm 
and are of endosomal origin, whereas microvesicles can be much larger (~50nm to1µm) 
and bud directly from the plasma membrane (1). EVs of all size types contain protein, 
nucleic acid, and lipid cargo (Korutla et al.; Minciacchi et al., 2015; van Niel et al., 2018) 
and exosomes, in particular, have been shown to exchange these molecules between cells 
to facilitate tissue cross talk. In this thesis, the term EVs will be used to refer to vesicles in 
the size range of exosomes unless otherwise mentioned.  
Several areas of research are actively investigating the role of EVs in intercellular 
communication and coordinated response to physiologic and pathologic stimuli. One such 
field is exercise physiology, where recent work has associated the release of EVs from 
skeletal muscle and other tissues during exercise (2). Regular exercise is known to improve 
health and reduce the risk of many diseases including type 2 diabetes, obesity, hypertension 
and some forms of cancer (3,4). The mechanisms underpinning the systemic health benefits 





in an autocrine/paracrine or endocrine manor to mediate the systemic benefits of exercise 
(6). A critical first step in elucidating the role that EVs play in mediating the health benefits 
of exercise via intercellular communication is fully characterizing the protein cargo of EVs 
released during exercise.  Although efforts have been made to characterize EVs released 
after exercise (7), methodological limitations including the use of non-platelet depleted 
plasma limit the reach of their findings.  
As mediators of intercellular communication, EVs are also involved in the 
pathogenesis of many diseases. EVs associated with obesity, a known risk factor for several 
diseases including diabetes, heart disease stroke and cancer (8,9), have been shown to 
modulate glucose and lipid metabolism (10) and are thought to mediate aspects of obesity-
related insulin resistance (11), a primary factor in the etiology of type 2 diabetes. Although 
a considerable amount of resources have been devoted to studying the role of obesity 
related EVs in the development of metabolic disorders, large knowledge gaps remain.  Prior 
to understanding the role of obesity associated EVs in metabolic disorders such as diabetes 
and anabolic resistance, mechanisms of local pathway dysregulation in insulin sensitive 
tissues such as skeletal muscle need to be further characterized.  
Several derangements in skeletal muscle are associated with obesity, including 
mitochondrial impairments, oxidative stress, insulin resistance, weakness, and fatigue.  
Exercise has been shown to improve these impairments, however, a significant percentage 
of individuals (15-20%) fail to realize the health benefits even when interventions are 
carefully controlled (12-15). This phenomenon, referred to as exercise resistance, is 





synthesis rates and anabolic responses following exercise and nutrition (16-18), which are 
probable contributing factors to the attenuation of adaptive responses to exercise. In this 
work, we utilized a multi-omics approach to characterize the differential response to 
exercise between lean and obese individuals with the goal of identifying dysregulated 
pathways that contribute to exercise resistance. This work will lay the foundation for future 
studies that aim to characterize the effect of EVs associated with obesity and their 
involvement in metabolic disorders.  
Another promising field of EV research is cancer, where growing evidence suggests 
that EVs play a critical role in tumorigenesis (19). In multiple myeloma (MM), there is an 
intense interest in EVs within the bone marrow micro environment (BMM) and their role 
in MM pathogenesis (20,21). It is now well established that alterations in the BMM 
facilitate tumor growth, angiogenesis bone disease and immune evasion (20-22) which 
promote disease progression, however, the role that EVs play in this process remains 
unclear and requires further characterization.  
To understand the role of EVs in physiological and pathological states, reliable and 
reproducible profiling of circulating EV molecular cargo is critically important. 
Interrogation of plasma EV protein cargo, however, is currently limited by the absence of 
optimal and reproducible approaches for purifying EVs from plasma that are suitable for 
downstream proteomic analyses. This thesis describes the development of a size exclusion 
chromatography (SEC)-based method to purify EVs from platelet poor plasma (PPP) for 
label-free proteomic analysis via high resolution mass spectrometry (SEC-MS). The 





standard, differential ultracentrifugation (UTC). We then applied SEC MS to characterize 
the abundance and composition of EVs released after single bouts of endurance and 
resistance exercise. Further, we performed a multi-omics study to characterize differences 
in the response to exercise between lean and obese individuals in skeletal muscle. This 
study will pave the way for future studies that aim to characterize the role of EVs in 
metabolic disorders. Finally, we utilized SEC-MS to identify EV based biomarkers of 
disease biology in patients with the hematological malignancy multiple myeloma (MM). 
The identified biomarkers have the potential to predict which patients are at risk of 
progressing from the precursor disease, multiple myeloma of undetermined significance 
(MGUS), to MM. If validated, these biomarkers will fill a critically needed role in the clinic 








Development and characterization of a platform for proteomic analysis of EVs 
isolated from plasma. EVs are membranous structures released from most cells that serve 
as vehicles to exchange protein, nucleic acid, and lipid cargo (24-26) between distant 
organs to facilitate intercellular communication. In order to characterize the protein cargo 
of EVs isolated form plasma, improved isolation techniques are required.  Currently, a 
variety of approaches are used by investigators to purify EVs from plasma (27), including 
ultracentrifugation and commercial kit-based isolations.  Many of these methods suffer 
from poor reproducibility or incompatibility with downstream analytical approaches, 
highlighting the need to establish a robust and reproducible approach for purifying plasma 
EVs to allow in-depth characterization and accurate quantification of their molecular 
content.  
While EVs derived from cell culture media can be isolated with high purity and in 
relatively large amounts (28), isolation of plasma derived EVs pose several unique 
technical and analytical challenges. For example, proteomic characterization of plasma 
derived EVs isolated with differential ultracentrifugation (UTC) has been confounded by 
the co-isolation of an overwhelming number of plasma protein contaminants (29,30).  
Proteomic analysis of EVs is also limited by notoriously low isolation yield due to EV loss 
associated with successive washing steps (31).  Alternative approaches include 
commercially available kits based on membrane affinity (32), polymer precipitation (33), 





downstream analyses, they are also incompatible with unbiased, in-depth characterization 
of EV proteins.  Size exclusion chromatography (SEC) based EV isolation was reported to 
rapidly isolate relatively pure EVs from plasma (35-37), and shown to produce exosomes 
that are suitable for downstream proteomics analysis (38,39).  Although this method is 
promising, post isolation processing methods need to be developed to allow for in-depth 
characterization of plasma EV cargo. Furthermore, optimized pre-analytical methods need 
to be coupled with sensitive high-resolution mass spectrometry analysis to achieve precise 
relative quantification of proteome differences between groups. Finally, there is a need to 
benchmark the analytical performance of the SEC method relative to other EV isolation 
approaches to serve as a resource for those interested in EV proteomics research.    
 
Another technical challenge of investigating plasma-derived EVs is the 
contribution of platelets, which are believed to contribute 70-90% of circulating EVs and 
are known to release EVs ex vivo when activated during sample handling procedures.  A 
particularly problematic issue is the several-fold increase in plasma EV concentration 
caused by platelets upon cooling/freezing (40,41).  This is especially important because 
cooling/freezing is a necessary pre-analytical step when analyzing a large number of 
plasma samples that require some interim storage.  To address this issue, rigorous pre-
analytical guidelines have been established by the International Society of Extracellular 
Vesicles (ISEV) and International Society on Thrombosis and Haemostasis (ISTH) to limit 





In the current study, we systematically evaluated an innovative approach using SEC 
coupled to high-resolution mass spectrometry (SEC-MS) for comprehensive proteomic 
characterization of human plasma EVs.  We address several important factors, including 
sample purity, method reproducibility, and downstream mass spectrometry analysis that 
are important for characterizing the EV protein cargo of large sample groups in both 
research and clinical settings. We also demonstrate the importance of following the 
rigorous pre-analytical guidelines established by the ISEV and ISTH to limit ex vivo 
generation of platelet EVs (40,42-44).  Additionally, sample processing steps downstream 
of EV isolation require careful attention due to the challenging nature of these samples.  
Finally, we address the lack of a benchmark for plasma EV proteomics method 
reproducibility and quantitative performance.  Toward this goal, we provide an optimized 
and reproducible method for isolating plasma EVs from human plasma that is suitable for 
downstream analysis of protein cargo.  To demonstrate the sensitivity of this analytical 
approach to detect physiological changes in exosome proteomic cargo, we evaluated the 
effects of acute exercise on proteome cargo of EVs isolated from human plasma samples.  
 
Results 
SEC Improves Plasma EV Proteomics Characterization. SEC is a low-
resolution, size-based, fractionation technique.  Larger EVs do not interact with the SEC 
resin and pass through the column rapidly, whereas smaller particles (e.g., plasma proteins) 
interact with the resin and pass through at a slower rate.  This separation enables improved 





reducing plasma protein contamination (45).  We investigated the proteomic profiling 
compatibility of plasma EVs that were isolated with SEC compared to several conventional 
plasma EV isolation methods.  We used platelet poor plasma (PPP) collected from a healthy 
donors in the resting state following overnight fast to reduce ex vivo contribution of 
platelets to the plasma EV population.  PPP was prepared as previously described (46) with 
modifications (see methods). EVs were also isolated from PPP by differential 
ultracentrifugation (UTC), SEC (qEV Original), polymer precipitation (ExoQuick), and 
membrane affinity (ExoEasy).  We show that SEC outperformed other methods, based on 
the ability to detect greater numbers of exosome proteins (defined by the Exocarta 
 
Figure 1. Size exclusion chromatography (SEC) improves plasma EV Proteomics 
Characterization. (A) Four commonly used methods were used to isolate EV’s from plasma of an 
individual healthy participant in the rested state for proteomics characterization. The highest number of 
total proteins (light blut bar) and proteins associated with the exocarta database (dark blue bar) were 





database; Figure 1A). Furthermore, SEC identified more canonical EV marker proteins 
(28) from less sample volume when compared to the UTC and ExoEasy methods (Figure 
1B).   
 
SEC-coupled mass spectrometry can reproducibly distinguish EV-associated 
proteins from plasma contaminants. To further characterize and optimize the SEC-MS 
assay, we analyzed the elution patterns of canonical EV marker proteins and plasma 
contaminants using SEC.  Fasting PPP (2 mL) was obtained from a donor, and plasma EVs 
were isolated using a qEV2 SEC column (Izon Science, Christchurch, NZ).  We collected 
individual 1 mL SEC fractions spanning the region where EVs elute from the SEC column 
(fractions 12-22) and processed them individually with a label-free proteomics workflow 
(see Methods).  The intensities of six canonical EV marker proteins measured in sequential 
SEC column fractions were used to generate SEC EV elution profiles (Figure 2A). The 
elution profiles of all six EV marker proteins show distinct peaks that co-eluted over seven 
distinct SEC fractions (fractions 15-21) (Figure 2A).  High molecular weight plasma 
protein contaminants such as fibrinogen, apolipoprotein B and IgM, also eluted in this 
region, however, the peak profiles of these common plasma contaminant proteins were 
right-shifted (Figure 2A), thereby differentiating them from the well-resolved EV marker 
SEC peaks. These results indicate that SEC can effectively separate exosomes from plasma 
contaminants. 
Orthogonal separation of the EVs and plasma contaminants by SEC was used to 





SEC-MS experiments. Toward this goal, a reference elution range was established for EVs 
using the ExoCarta top 100 (ECT100), a list of the most commonly observed proteins in 
exosomes (47).  79 of 84 ECT100 proteins detected displayed Gaussian shaped profiles 
which reached their intensity apex, an indicator of maximum abundance, between fractions 
17 and 19 (Figure 2B, C). The five ECT100 proteins that reached intensity apexes outside 
of fractions 17-19 exhibited chromatographically distinct peak profiles (data not shown) 
that were mainly associated with the delayed elution of plasma contaminants, rather than 
EV derived proteins. These proteins also have high molecular weights and high plasma 
concentrations (A2M, FN1) or the ability to form multi-molecular complexes (THBS-1 
and LGALS3BP) (48,49).  The large size and chromatographic association with plasma 
contaminants suggests that these proteins may be of plasma origin, rather than EV derived. 
Consistent with this concept, serum albumin, a known plasma contaminant and ECT100 
protein, exhibited an elution profile that was distinct from all other ECT100 proteins. 
Further review of all proteins co-eluting with albumin revealed that none of them were 
associated with ECT100, and that fraction contained several abundant erythrocyte proteins 
such as hemoglobin, band 3 anion transport protein, and peroxiredoxin-2 (50). These 
observations suggest that erythrocyte fragments and large protein aggregates containing 
albumin elute before EVs.  Hence, we determined that the reference EV SEC elution range 
was between fractions 17 and 19 and all proteins in the dataset with an apex falling within 
this fraction range were extracted and categorized as “EV-associated proteins.” Finally, 
high molecular weight proteins (> 200kDa), proteins known to form large complexes 







Figure 2. SEC separation of EV’s from plasma proteins. (A) SEC fraction profiles of several EV 
markers and high molecular weight plasma proteins to illustrate separation of EV’s from plasma proteins. 
Profiles are generated from protein intensities of individually analyzed 1ml fractions across the EV 
elution range. (B)  Bar plot of intensity apex vs SEC fraction for proteins in the Exocarta top 100 
(ECT100) show where EV’s are eluting from the SEC column. (C)  Schematic of a bioinformatics based 
filtering process to identify potential contaminant proteins. Proteins remaining after the filtering process 







hemoglobin) were filtered out (Figure 2C).  After the filtering process, 454 of the original 
758 identified proteins remained (Figure 2C). EV-associated proteins were less abundant 
than contaminants (EV associated proteins: median=32ng/ml, interquartile range [IQR] = 
7.0-180ng/ml; contaminants: median = 28µg/ml, IQR = 0.21-290µg/ml, p = 2.2e-16). 
Considering these characteristics, it is reasonable to hypothesize that the proteins with apex 
intensities within SEC fractions 17-19 are contained within a vesicle. It should be noted, 
however, that it may be possible for some proteins to be associated with both EVs and the 
EV-independent plasma proteome.  In comparison to the co-migration based filtering, 686 
of the 758 proteins were contained in the Exocarta database, suggesting that this peak 
filtering strategy is a more conservative, but more accurate strategy to distinguish between 
EV and contaminant proteins.  
We evaluated the reproducibility of SEC separation using three replicate PPP 
samples processed using three different SEC columns.  Each replicate PPP sample was 
processed with each SEC column, and individual 2ml fractions between 12-23 were 
collected.  Each collected fraction was subjected to proteomics analysis, and protein SEC 
elution profiles were constructed to determine reproducibility of EV separation.  In total, 
85 of the ECT100 proteins were identified in each replicate, and their elution profiles were 
highly correlated both within the same SEC column and across SEC columns (Figure 3A, 
B-C). Furthermore, the 4 ECT100 protein identified as possible plasma contaminants 
above (A2M, FN1, THBS1, LGALS3BP) displayed reproducible shifts in elution 
differentiating them from all other ECT100 proteins (data not shown).  We also assessed 





summed the intensity of each protein observed in each sample across all six fractions of 
each SEC column.  The median coefficient of variation (CV) of protein intensities was 
 
Figure 3. SEC Separation is reproducible across columns. Three separate SEC columns were used to 
analyze 3 replicate platelet poor plasma (PPP) samples collected in six individually processed fractions 
across the EV elution range. (A) 85 exocarta 100 (ETC100) proteins were identified in each replicate and 
elution profiles were highly correlated across each column. (B) Elution profiles for several commonly 
observed EV proteins are also highly correlated across columns. (C) CV’s calculated from summed 






20.89 (IQR 16.75-30.54), which is within the acceptable limits of typical label-free 
proteomics experiments (51-53).  
 
Figure 4. Mass spectrometry analysis of unfractionated extracellular vesicles (EV’s) and EV’s 
fractionated by size exclusion chromatography (SEC) yield similar results. A reproducibility and 
performance comparison was performed for fractionated and unfractionated EV’s. EV’s were isolated 
from replicate plasma samples using three different SEC columns. (A) Bar chart displaying similar 
numbers of protein identifications resulting from unfractionated EV’s (n=3) and EV’s fractionated by 
SEC (n=3). (B) Venn diagram displaying the protein identification overlap observed between the 
unfractionated and fractionated EV’s. (C) Coefficient of variation (CVs) calculated from the replicate 
measurements display comparable precision between the unfractionated and fractionated EV’s. (D) Table 





Collecting and analyzing individual SEC fractions is labor intensive, error prone, 
and restricts sample throughput.  To streamline SEC-based exosome analysis, we tested 
the feasibility of pooling the EV-containing SEC fractions together as one sample for 
subsequent proteomic analysis.  For this, SEC fractions 14 to 21 obtained from three 
additional replicates of the above reproducibility experiment were pooled as a single EV 
sample for each replicate.  We identified a similar number of proteins when analyzing 
pooled or individual SEC EV fractions (pooled: 800±46, fractions: 826±23; Figure 4A), 
with a majority (76%) of proteins identified by both types of sample analysis (Figure 4B).  
Importantly, the CV of protein intensities was slightly better when analyzing a pooled EV 
sample versus individual EV fractions of a single sample (Figures 4C, 4D). Taken 
together, these results indicate that EVs elute from SEC columns in a predictable and 
quantitatively reproducible manner that is amenable to downstream mass spectrometry 
analysis of pooled SEC fractions.   
 
SEC-MS increases EV protein identifications and precision compared to 
ultracentrifugation. The performance of SEC-MS in isolating EVs for proteomic analysis 
was compared to the conventional ultracentrifugation (UTC) approach. EVs were isolated 
from pooled PPP acquired from healthy donors (n = 2) in the rested and fasted state using 
SEC and UTC. Five replicate measurements were performed.  Nanoparticle tracking 
analysis showed similar particle size for both methods (SEC: 78 ± 12nm, UTC: 82 ± 14nm, 
P= 0.90).  However, particle counts were higher for SEC compared to UTC (SEC: 1.49e10 





of EVs with SEC compared to UTC.  EVs isolated with SEC also appeared to be intact and 
have a diameter of less than 100nm by transmission electron microscopy (Figure 5C).  
Proteomics analysis revealed that SEC produced significantly more protein identifications 
than UTC (SEC: 1268 ± 102, UTC: 319±45, p= 2.6E-6) (Figure 5D).  The CV of the 
 
Figure 5. Comparison of extracellular vesicle protein identifications following size-exclusion 
chromatography and ultracentrifugation. Size distribution (A) and particle count (B) characterization of 
extracellular vesicles (EVs) isolated from platelet poor plasma (PPP) using size-exclusion 
chromatography (SEC) or ultracentrifugation (UTC) by nanoparticle tracking (NTA). (C) Transmission 
electron microscopy (TEM) image of EV isolated from plasma using SEC. (D) Experiments from five 
replicate analyses of pooled PPP showed that SEC produced approximately 3-fold more identifiable 
proteins compared to UTC. Dark blue bars represent the total number of protein identifications for each 
replicate, while light blue bars represent the number of the identified proteins which associate with the 
Exocarta database. (E)  Histogram displaying the coefficient of variation (CV) calculated from protein 
intensity measurements of the five replicate measurements. In total, 562 proteins with a CV of less than 
25% were identified with SEC, compared to just 73 with UTC. (G) CVs for several EV marker proteins 
identified by SEC and UTC. (F) Protein identifications from each method plotted as ranked abundance 





protein intensities obtained from SEC-MS was significantly lower than those obtained via 
UTC-MS (Figure 5E).  In total, 562 proteins quantified by SEC-MS had CVs less than 
25% when compared to only 73 proteins reaching this threshold for the UTC-MS.  
Moreover, CVs of canonical EV marker proteins were lower with SEC-MS when compared 
to UTC-MS (Figure 5F).  A closer inspection of the canonical EV protein marker intensity 
data suggested that UTC-MS was either unable to detect these proteins or detected them 
with a lower intensity when compared with SEC-MS, which resulted in a higher CV for 
these proteins (Figure 5G).  This is suggestive of suboptimal EV recovery with UTC, 
which was noted by others (31).   
SEC-MS Measurements are Linear and Precise. SEC-MS outperformed the 
conventional UTC-MS approach for plasma-derived EV proteomic analysis. To test the 
quantitative performance of SEC-MS across a range of EV abundance, human plasma was 
serial-diluted with exosome-depleted bovine serum (EDBS).  For this experiment, non-
platelet depleted plasma was used (i.e., platelet rich plasma PRP), to extend the top end of 
the EV dynamic range. Five replicates of a dilution series (neat plasma, x2, x4, x8 and neat 
EDBS) were generated, and each dilution series replicate was processed using a separate 
SEC column.  With this design, it was possible to simultaneously assess reproducibility 
across SEC columns and linearity of the dilution. More than 2,080 proteins were detected 
across the experiment, and 1,418 proteins remained after filtering out proteins that were 
indistinguishable from bovine proteins based on the observed peptide evidence.  Protein 
intensities of multiple canonical EV proteins displayed linear curves across the dilution 





an r2>0.9 (Figure 6B), indicating high linearity across the quantitative range.  Protein 
 
Figure 6. Evaluation of quantification performance in biological samples. (A) Pooled human plasma 
was serially diluted with exosome-depleted fetal bovine serum (EDFBS) and extracellular vesicles (EVs) 
were isolated from five replicates of each dilution level. Dilution curves fit with a linear regression are 
displayed for several select EV marker proteins.  Average protein abundance values at each dilution point 
were used to fit the curve. (BC) Histogram representing mean R2 values of the replicate dilution curves 
for all identified proteins showed 850 proteins had an R2 value > 0.9. (CD) Analysis of the coefficients 
of variation (CVs) of the five replicate measurements at each dilution point showed low variation at each 
dilution point. (D) Linear regression showing the high correlation between summed EV protein intensity 
and dilution factor. Correlation is much higher when contaminants identified using the co-migration 
based filter process are removed prior to summing protein intensity (contaminants filtered; R2 = 0.992 





intensity precision of replicate measurements at each dilution point was also measured.  
This analysis identified 564, 564, 424 and 239 proteins with CVs less than 25% at the neat 
plasma, x2, x4 and x8 dilution points, respectively (Figure 6C). To test the potential for 
using total EV associated protein intensity as a measure of overall EV abundance, the total 
intensities of all EV associated proteins (i.e. proteins remaining after filtering contaminants 
identified by the co-migration based filtering process described above) observed in a 
sample was plotted against its dilution factor (Figure 6D).  Summed EV associated protein 
intensity was highly correlated with the dilution factor (r2 = 0.992), indicating that this 
approach may provide an accurate readout of total EV abundance. Plotting summed EV 
plus contaminant protein intensity for each sample against the dilution factor produced a 
lower r2 of 0.815, reinforcing the notion that the co-migration based filtering process is 
useful for identifying contaminants. 
 
EVs derived from different cell types contain both common and unique 
protein cargo. Cell culture-based EV experiments were performed to identify EV proteins 
that may be unique to specific EV-producing tissues (e.g., platelets, skeletal muscle, 
adipose, liver, leukocytes).  EVs were isolated from media collected from cultured primary 
human myotubes, primary human adipocytes, Huh7 hepatocytes, leukocytes, and isolated 
human platelets, and their protein cargo was profiled using SEC-MS.  Many identified EV 
proteins were common to all cell types, but a large number of putative cell-specific EV 
proteins were also identified (Figure 7A).  A total of 118, 310, 350, 180 and 121 unique 





respectively. Gene ontology (GO) overrepresentation enrichment analysis (ORA) of 
putative cell-type specific EV proteins revealed several distinct gene sets including actin 
filament-based movement and muscle structure development (myotube), proteolysis 
(adipocyte), intracellular transport (hepatocyte), blood coagulation (platelet), and immune 
effector process (Leukocyte) (Figure 7B).  Putative cell-specific EV proteins were merged 
with tissue specific proteins from The Human Protein Atlas (HPA) (54). Prior to merging 
putative cell-specific EV proteins with HPA data, proteins which were unique to the 
 
Figure 7. Comparison of EV protein content from different cell types. (A) Venn diagram showing 
the protein composition overlap of extracellular vesicles (EVs) isolated from primary human myotube, 
primary human adipocyte, HUH7 hepatocyte, platelet and leukocyte conditioned medium (CM). While 
many of the identified proteins were common to several cell types, some were unique to each. (B) Over 
representation enrichment analysis (ORA) of proteins identified uniquely in each cell type identified 





combined list of platelet plus leukocyte EVs (platelet + leukocyte specific proteins) were 
determined because HPA considers “blood” as one tissue. HPA “tissue enhanced” and 
“tissue enriched” data aligned with 67 myotube (“muscle” in HPA) and 120 platelet + 
 
Figure 8. Bar plots illustrating the agreement between Human Protein Atlas tissue specific data and 
putative cell-line specific EV data from the current study. Each bar plot illustrates tissue specificity 





leukocyte (“blood” or “lymphoid” in HPA) specific proteins EV proteins, whereas only 4 
adipocyte (“adipose” in HPA) and hepatocyte (“liver” in HPA)  putative cell-specific EV 
proteins each agreed with HPA data (Figure 8). These data are a valuable resource in 
efforts to track the composition and origin of circulating EVs.  
 
Platelet and leukocyte derived EVs are abundant in plasma and can be released ex 
vivo. Ex vivo platelet activation is a well characterized phenomenon with implications in 
 
Figure 9. Differential comparison of extracellular vesicle proteins derived from platelet poor and 
platelet rich plasma. (A) Mass spectrometry analysis of extracellular vesicles (EVs) isolated from six 
replicates of pooled platelet-poor plasma (PPP) or platelet-rich plasma (PRP) showed significantly 
increased protein identifications in PRP. (B) Volcano plot representing the relative difference in protein 
abundance between PPP and PRP. Proteins identified only in EV’s derived from isolated platelets or 
leukocytes are colored in blue to show illustrate the overwhelming increase in abundance of platelet and 
leukocyte derived EVs in PRP plasma. (C) Table showing the number of identified and upregulated 





transfusion medicine and blood processing.  Several fold increases in platelet derived EVs 
have been observed following freeze-thaw of standard plasma (i.e., platelet rich plasma; 
PRP) (40,41).  Obtaining unfrozen plasma to avoid platelet EV release prior to EV analysis 
 
Figure 10. Aerobic exercise triggers an increase in extracellular vesicle protein abundance. (A) 
Volcano plots showing the increase in EV-associated protein abundance immediately after exercise for 
aerobic and resistance exercise. (B) Summed EV-associated protein intensity normalized to pre-exercise 
is displayed for aerobic and resistance exercise. Summed EV-associated protein is significantly increased 
after exercise (p= 0.0006) and returns to pre exercise levels by 3hr. (C) Venn diagram showing common 





is logistically difficult for human studies.  Hence, it is important to assess the effect of 
platelet depletion on SEC-MS toward the goal of making SEC-MS compatible with frozen 
plasma samples.  Blood was collected from two healthy volunteers, pooled, and divided to 
be prepared as PPP or PRP.  EVs were isolated and analyzed from six replicate samples of 
each preparation type using SEC-MS.  As expected, the average number of protein 
identifications was significantly higher in the PRP relative to the PPP (PRP = 1147 ± 20, 
PPP = 877 ± 32, p = 6.0E-8) (Figure 9A).  Furthermore, the abundance of platelet + 
leukocyte specific proteins were significantly higher in the standard plasma compared to 
PPP (Figure 9B).  In total, 308 platelet + leukocyte specific proteins were identified in the 
PPP vs PRP comparison.  Of these, 124 were significantly increased in PRP relative to PPP 
> log2FC of 1.0.  These results provide evidence that platelet and  leukocyte-derived EVs 
released ex vivo account for a majority of the increased EV proteins observed in standard 
plasma (i.e., PRP). 
 
Acute exercise triggers EV release. We applied the SEC-MS method to evaluate 
the effect of acute exercise as a physiological stimulus on plasma EV proteome cargo in 
humans. The effects of exercise on EV release into circulation has been investigated by 
others (7,55), and we considered acute exercise as an appropriate physiological 
intervention to determine the ability of the approach to detect the EV proteome changes. 
Although the objective was not to compare and contrast with the previous reports, 
we wanted to determine whether the current PPP-SEC-MS approach with its 





from human EVs released following exercise. Moreover, we also sought to identify the 
specific cellular origin of many EV proteins.  We determined the differential responses of 
EV protein abundance following one bout of acute high intensity aerobic (aerobic: n = 14) 
and a moderate bout of single leg resistance exercise (resistance: n = 16) (Supplement table 
7).  
 Fourteen healthy individuals performed a single bout of aerobic exercise at ~90% 
of VO2 peak (56), and samples were collected before exercise (pre), within 10 min  
(immediately-post), 1hr (post-1hr), and 3hr (post-3hr) following exercise.  Sixteen 
Term Count PValue 
Fold 
Enrichment FDR 
Biocarta: mPRPathway:How Progesterone 
Initiates the Oocyte Maturation 17 3.02E-08 4.865269 6.55E-06 
Biocarta: salmonellaPathway:How does 
salmonella hijack a cell 10 4.93E-07 7.48503 5.35E-05 
Biocarta: uCalpainPathway:uCalpain and 
friends in Cell spread 11 9.87E-07 6.296231 7.14E-05 
Biocarta: actinYPathway:Y branching of 
actin filaments 12 1.31E-06 5.560308 7.10E-05 
Biocarta: rhoPathway:Rho cell motility 
signaling pathway 15 1.78E-06 4.292885 7.74E-05 
Biocarta: cskPathway:Activation of Csk by 
cAMP-dependent Protein Kinase Inhibits 
Signaling through the T Cell Receptor 12 2.39E-06 5.307567 8.64E-05 
Biocarta: integrinPathway:Integrin Signaling 
Pathway 15 5.93E-06 3.944813 1.84E-04 
Biocarta: cdc42racPathway:Role of PI3K 
subunit p85 in regulation of Actin 
Organization and Cell Migration 10 5.99E-06 6.081587 1.63E-04 
Biocarta: monocytePathway:Monocyte and 
its Surface Molecules 8 2.38E-05 7.076756 5.75E-04 
Biocarta: neutrophilPathway:Neutrophil and 
Its Surface Molecules 7 2.46E-05 8.514222 5.33E-04 
Biocarta: lymphocytePathway:Adhesion 
Molecules on Lymphocyte 7 6.75E-05 7.568197 0.00133 
Biocarta: mCalpainPathway:mCalpain and 
friends in Cell motility 10 1.51E-04 4.422972 0.002726 
 
Table 1.  Related to figure 11. Significantly enriched functional annotations after aerobic exercise 





additional individuals performed a single bout of unilateral knee extensor resistance 
exercise consisting of 3 sets of 10 repetitions at 70% of their 1-repetition maximum (1RM) 
(Robinson et al., 2017).  Each participant’s 1RM was determined at least 7 days, but no 
more than 30 days prior to the study visit.  Samples were collected before (pre), within 10 
min (immediately-post), 30min post (post-30min) and 60 min (post-60min) following 
exercise. All samples were analyzed by PPP-SEC-MS. We identified 2736 proteins in the 
aerobic exercise group (Figure 10A). Time course analysis of the response to aerobic 
exercise utilizing summed EV associated protein intensity showed a significant increase in 
circulating EV protein abundance immediately following aerobic exercise (p=0.0006), 
which returned to pre-training levels by 3hr post-exercise (Figure 10B). Notably, a similar 
trend was observed in ADAM10 positive particles measured by nano-flow cytometry 
(nFLC) immediately after training (p=0.055; data not shown).  Conventional nanoparticle 
tracking analysis (data not shown) did not reveal the same post-exercise increase in particle 
count as summed EV protein intensity of nFLC. This suggests that SEC-MS and nFLC are 
more sensitive methods for detecting shifts in EV abundance with exercise compared to 
particle counting. The immediately-post aerobic exercise time-point revealed an increase 
in the abundance of 321 EV-associated proteins (Figure 10A). Functional enrichment 
analysis of these proteins indicated that they are central to CDC42 mediated cell migration, 
integrin signaling and immune function as indicated by enrichment of lymphocyte adhesion 
molecules, monocyte surface molecules and regulation of T-cell activation (Table 1). 
Similarly, Ingenuity Pathway Analysis (IPA) showed that these proteins were enriched for 





signaling. Additional pathways including glycolysis and signaling via Rho GTPase, IL-8, 
and integrin were also differentially regulated by exercise (data not shown).  We next 
overlaid these data with the cell-type specific EV data we generated previously (Figure 
7A) to assess the source of circulating EV proteins. When using cell type-specific EV 
proteins, we found proteins specific to myotubes (96), hepatocytes (58), adipocytes (59), 
leukocytes (189), and platelets (93) (Figure 11A). Interestingly, at the immediate post 
 
Figure 11. Cell specific EV proteins are upregulated after aerobic exercise. (A) Volcano plot 
illustrating the increase in EV protein abundance after aerobic exercise. Proteins identified uniquely from 
each cell type (Figure 5) are highlighted in individual volcano plots and significantly upregulated proteins 
(log2FC > 0.5) are labeled. (B) Table showing the number of identified and upregulated proteins form 







exercise time point we found significantly upregulated proteins that were specific to each 
cell type profiled, including 30 leukocyte EV-specific and 5 myotube EV-specific proteins, 
of which 19 and 3 were supported by HPA tissue specific data respectively, demonstrating 
that EVs from different tissues can be measured in the plasma circulation. Collectively, 
these data highlight that one session of high intensity aerobic exercise leads to robust 
changes in circulating EV protein abundance, which may play an important role in 
regulating the metabolic and immune responses of training. 
  The samples of from the single leg resistance exercise analysis identified 3138 total 
proteins. EV-associated protein intensity displayed an upward trend post exercise, 
however, this increase failed to reach significance (p = 0.17) (Figure 10B). Analysis of the 
post resistance exercise time point found only 7 proteins which significantly were 
upregulated and 1 protein which was down-regulated, in stark contrast to the robust 
increase of EV proteins triggered by the acute bout of aerobic exercise (Figure 10A). Of 
the 7 upregulated proteins, 3 were commonly upregulated by the aerobic exercise bout 
(Figure 10C). Interestingly, 2 of the 3 commonly upregulated proteins were found to be 
specific to leukocytes in our cell type specific experiments further implicating immune 
modulation in response to different modes and intensities of exercise.  Among the 
upregulated proteins common to both exercise responses was MMP9 (Matrix 
metallopeptidase 9) which is involved in functions that include neutrophil action, 







Here we describe an optimized SEC-MS method for proteomic analysis of plasma 
EVs that offers superior quantitative performance and reproducibility compared to 
conventional EV analytical approaches. Importantly, this SEC-MS method exhibited 
linearity over a biologically relevant dynamic range and is sensitive to small differences in 
protein abundance. Additionally, the orthogonal separation of EVs and plasma protein 
contaminants provided by the SEC column was leveraged to filter contaminants from 
plasma proteins within the EV proteome. Using SEC-MS, we demonstrate the importance 
of using PPP to avoid the confounding effects of ex vivo release of platelet EVs.  After 
benchmarking quantitative performance of SEC-MS, we used the method to demonstrate 
the time-related effects of two different modes and intensities acute exercise bouts on 
changes in plasma EV protein abundance  
The proteomic depth of plasma EVs isolated with UTC or commercially available 
kits is limited by factors including plasma protein contamination and low EV recovery 
(Figure 1).  We show that SEC purification of EVs followed by proteomic analysis 
substantially mitigates plasma protein contamination.  Particle counts, EV protein 
intensities, and EV protein identifications were markedly higher when plasma EVs were 
isolated with SEC compared to UTC (Figure 5A-B, D).  Further, the precision of replicate 
SEC-MS measures is far superior to that based of UTC-MS; capable of quantifying >500 
proteins with CV less than 25% (Figure 5E). 
Beyond demonstrating utility of SEC for isolating EVs, we also present a strategy, 
based on the fractionation properties of SEC, to distinguish EV-associated proteins from 





relies on identification of proteins that co-elute with known EV proteins, allowing us to 
reproducibly identify four proteins in the ECT100 as likely plasma protein contaminants, 
rather than EV derived proteins.  However, we cannot categorically exclude the possibility 
that some proteins may be commonly present in both EVs and plasma proteome.  
Nevertheless, the SEC-MS method can discern if the majority of the protein abundance in 
a sample is derived from plasma contaminants or EVs. This is particularly useful because 
accurate EV abundance measurements are obtained by filtering contaminants and summing 
EV-associated protein intensities (Figure 6C).  Additionally, SEC-MS can also be used to 
validate whether a candidate protein is derived from EV, with an added advantage of being 
applicable for any EV protein and not limited to EV membrane proteins. There are previous 
reports (7,39) of the relative quantification of plasma EV proteome.  However, the 
quantitative performance of those methods has not been described. We benchmarked the 
quantitative performance of SEC-MS to validate it for relative quantification of EV 
associated proteins in biological samples. Using a dilution series experiment, we show that 
over 850 EV proteins can be measured from human plasma with an r2> 0.9.  We also 
observed low quantitative CVs at multiple dilution points indicating high precision.  Ex 
vivo activation of platelets is known to cause a massive release of EVs, resulting in sample 
contamination and confounding results.  To avoid this issue, ISEV and ISTH guidelines 
recommend including a platelet depletion step prior to refrigerating plasma. Although this 
step is strongly recommended and widely recognized by the EV research community, 
several recent studies examining the plasma EV proteome have utilized frozen serum or 





well characterized previous studies. In order to assess the extent of platelet-derived EVs 
released during sample processing, we performed a differential analysis on pooled plasma 
with and without platelet depletion using SEC-MS. The detected proteins were also cross-
referenced with platelet + leukocyte specific EVs derived from the cell culture-based EV 
experiment. This analysis showed large increases in platelet and leukocyte specific EV 
protein identifications and abundances in non-platelet depleted plasma relative to PPP.  
These results highlight the importance of the platelet depletion step to avoid sample 
contamination and confounding results. This study demonstrates that the SEC-MS offers 
an opportunity to analyze the PPP EV proteome, which contains fewer EVs but more 
accurately reflects the composition of circulating EVs.  
We applied SEC-MS to characterize the acute effects of a single bout of high 
intensity aerobic exercise or resistance exercise on plasma EV proteome.  We identified 
3409 proteins in this experiment using a short 1hr MS method; substantially shorter than 
UTC-MS methods described previously (7).  In the present study, >300 proteins were 
significantly increased following a single bout of aerobic exercise.  We also noted that 
acute single-leg resistance exercise bout increased only 7 EV proteins although three of 
them are common to both exercise modes.  Increased cardiac output and more dynamic 
nature and high intensity (90% of VO2peak) of aerobic exercise is a likely reason for the 
substantially more robust response to aerobic exercise in comparison with the response to 
the modest one-leg resistance exercise.  Although the goal of this exercise was not to 
contrast the effects of exercise modality on circulating EV cargo, it is interesting to note 





intensity, short duration bout of single leg resistance exercise.  We also performed cell 
culture-based EV profiling experiments and identified candidate tissue-specific proteins 
that are released immediately after an aerobic exercise bout. Although skeletal muscle 
contributed to the circulating EV pool, it is of great interest that EV proteins specific to 
other tissues including leukocytes were dominant following a bout of aerobic exercise and 
linked these proteins with important functions including signaling, immunological 
response, repair and angiogenesis.  How aerobic exercise interacts with other tissues, 
especially leukocytes, remains to be determined. It has been shown that exercise-induced 
muscle tissue damage attracts many circulating cells, including those involved in 
immunological reactions that remove degraded proteins and stimulate protein synthesis 
(59). It appears that acute exercise stimulates these circulating cells to release proteins via 
EVs which may enable the transport of important signals to multiple organs. It remains to 
be determined whether these signals contribute to the exercise responses in remote organs 
such as liver and brain. Also, the exact mechanism of exercise-mediated EV release from 
liver, adipocytes and platelets also remain to be determined.  
In summary, our study describes the development and quantitative performance of 
a reproducible SEC-MS assay for plasma EV protein analysis.  We demonstrate that this 
assay yields deeper proteomic coverage and higher precision when compared to more 
commonly used approaches, especially UTC-MS. Our study makes an important advance 
in the quest to determine the tissues of origin of EVs found in circulation. We demonstrate 
the importance of platelet poor plasma to avoid ex vivo contamination from platelet derived 





based exosome isolation. We benchmarked the quantitative performance of SEC-MS and 
demonstrate that it can be usefully employed in human clinical studies. Finally, we 
demonstrated the EV proteome response to acute bouts of exercise, and future studies will 
be needed to determine the effects of exercise intensity, duration, and modality on the 




This study was approved by the Mayo Clinic Institutional Review Board and 
conducted in accordance with the Declaration of Helsinki. For method development and 
analytical validation, blood was collected from a group of volunteers composed of both 
males and females.  For the high intensity aerobic exercise study seven male and seven 
female subjects were recruited. For the resistance exercise study eight male and eight 
female subjects were recruited.  Subject characteristics are summarized in Table S7. 
 
Measurement of VO2 max. 
VO2max was measured with indirect calorimetry (Medgraphics Diagnostics) using 
an electronically braked cycle ergometer (Lode Medical Technologies).  VO2max was 
defined as reaching a perceived exertion > 17 on the Borg RPE scale with an RER > 1.1 
(mean ± SD [Range]: 1.17 ± 0.02 [1.15–1.19]), and achieving a heart rate within 10% of 






High intensity aerobic exercise 
Subjects completed one bout of high intensity cycling (4 bouts of 4 min at > 90% 
of VO2max with 3 min pedaling at no load between bouts), as previously described (56).  
 
Acute resistance exercise 
Subjects completed one bout of one-legged knee extension exercise (3 sets of 10 
repetitions at 70% of 1-repetition-maximum, with 1min rest in-between sets).  
 
Cell culture 
Human skeletal muscle myoblasts (HSMM) were purchased from Lonza and grown 
in skeletal muscle cell growth medium (Cell Applications, cat# 151K-500).  Media was 
changed three times a week until he cells reached 70% confluency at which point they were 
differentiated to myotubes in Dulbecco's Modified Eagle Medium/F-12 (DMEM/F-12) 
containing penicillin(100 U/mL), streptomycin(100 ug/mL) and 2% horse serum.  After 
differentiation the cells washed twice with PBS and were placed back into growth medium 
supplemented with 2% exosome depleted bovine serum (EDBS,Gibco,cat# A2720801 ).  
After 24hours the media was harvested and frozen. 
Human pre adipocytes were cultured in preadipocyte growth medium-2 (PGM-2 
Bullekit, Lonza cat# PT-8002) and the media was changed 2-3 times a week until the cells 
reached 80-90% confluency.  The preadipocytes were differentiated to adipocytes 
according to the manufactures instructions.  Once differentiated, the cells were washed 





(Gibco,cat# A2720801 ) and cultured for an additional 24hrs before the media was 
collected and frozen.   
Isolated platelets were obtained from the Mayo Clinic blood bank.  Platelet EVs 
were prepared as previously described (60).  Briefly, the isolated platelets were washed 
with 3x in Tyrode-HEPES buffer (145mM NaCl, 2.9 mM KCl, 10mM HEPES, 1mM 
MgCl2, 5mM glucose, pH 7.3) and re-suspended at a concentration of 6X10
8/ml.  Platelets 
were activated with thrombin (0.1U/ml) and incubated at 37°C for 30min with rotation 
every 10min.  Platelets were then pelleted by centrifugation at 3200x g for 10min and the 
supernatant was collected and frozen at -80°C.  
Huh7 hepatocytes were cultured in DMEM containing glucose(4.5 g/L) 
penicillin(100 U/mL), streptomycin(100 ug/mL) and 10% fetal bovine serum (FBS).  Cells 
were grown to 90% confluency on 150mm tissue culture dishes. Cells were washed twice 
with PBS and then cultured for an additional 24hr in growth medium supplemented with 
5% extracellular vesicle-depleted FBS, which was prepared by overnight centrifugation at 
100,000g at 4C and 1% bovine serum albumin. 
Human leukocytes were isolated from blood donated by two donors.  Whole blood 
was drawn into 10-ml ETDA tubes and placed on the benchtop for 15minutes.  After 
15minutes each tube was centrifuged at 2,000xg for 10min at room temperature (RT) to 
pellet red blood cells.  The buffy coat was isolated from 10 blood collection tubes and 
transferred to a 50ml Falcon tube.  Cells were then re-suspended in 25ml of PBS, pelleted 
at 2,000xg and transferred to a new tube 3x to remove as many red blood cells as possible.  





800rpm.  The supernatant was then removed and this process was repeated 3x to remove 
platelets.  Isolated leukocytes were then re-suspended in 10ml of PBS and placed on ice 
for 1.5hr.  The supernatant containing the EVs was then collected for further processing.   
 
EV isolation from cell culture media 
Myotube, adipocyte, hepatocyte, platelet and leukocyte conditioned media were 
centrifuged at 2,000xg for 10 minutes to pellet cell debris.  The media was then transferred 
to a new tube and centrifuged at 10,000xg for 20min to pellet large vesicles.  The media 
was then filtered through a 0.2µm filter.  Myotube, adipocyte, hepatocyte and platelet 
media were transferred to a 70-ml 100kD Centricon® Plus-70m filter unit to concentrate 
the media as previously described (61).  The concentrated media was then diluted up to 
2ml at which point the EVs were isolated using a qEV2.0 (Izon) size exclusion 
chromatography column and processed as described from plasma EVs.  Leukocyte and red 
blood cell EVs were processed by ultracentrifugation UTC. Briefly, samples were pelleted 
at 10,000 x g to pellet large vesicles. The supernatant was transferred to a new tube and 
centrifuged at 100,000 x g for 1.5hr and digested as described for plasma EVs.   
 
Blood collection and plasma preparation 
Whole blood was drawn into ETDA tubes and placed on the benchtop for 
15minutes.  After 15minutes each tube was centrifuged at 2,000xg for 10min at room 
temperature (RT) to pellet red blood cells.  The upper plasma fraction was then collected, 





poor plasma was isolated by carefully transferring the top layer of plasma to a new tube 
and then frozen at -80°C in 1ml aliquots. 
 
Isolation of plasma extracellular vesicles by size exclusion chromatography (SEC) 
Frozen platelet poor plasma was removed from the freezer, thawed on ice and 
centrifuged at 2,000xg for 10 min to pellet debris.  The plasma was then transferred to a 
new microcentrifuge tube and centrifuged at 10,000xg for 10min to pellet larger vesicles.  
Following centrifugation the plasma was transferred to a new tube and placed on ice until 
analysis.  Extracellular vesicle isolation was performed using a qEV 2.0 size exclusion 
chromatography column (Izon Science, Christchurch, New Zealand) following the 
manufactures protocol.  Briefly, SEC columns were equilibrated to room temperature and 
flushed with 90ml of phosphate buffered saline (PBS) before use.  Platelet poor plasma 
(time course analysis: 1.2ml, all other experiments: 2.0ml) was transferred into the sample 
loading reservoir of the SEC column.  The column cap was then removed and the plasma 
sample was allowed to completely enter the column, at which point the sample loading 
reservoir was filled with PBS.  The first 13ml of PBS fraction was discarded and the 
following 8ml’s of EV containing fraction were collected for each sample.  The SEC 
columns were then flushed with 90ml of PBS before the addition of the next sample.  The 
8ml of EV containing fraction for each sample was then pelleted by ultracentrifugation at 
100,000xg for 1.5hr at 4°C.  Following ultracentrifugation the supernatant was discarded 






Nano-particle tracking analysis (NTA) and transmission electron microscopy (TEM) 
EVs isolated by SEC were measured by NTA using a 10 fold dilution of the SEC 
column eluate.  EVs isolated by UTC were re-suspended in PBS prior to measurement.  All 
NTA measurements were obtained using a Nano-sight LM10-HS with a 532nm laser 
running on NTA software v3.2.  Samples were diluted until they reached the manufacturers 
recommended concentration of 20-60 particles per frame and data was acquired in 3 x 
60sec videos with a viscosity of 0.985-0.897cP, cameral level 13, detection threshold 2 and 
temperature of 25°C.  For TEM, a 1ml volume of SEC column eluate was fixed with 16% 
paraformaldehyde (4% final).  The sample (5µl) was deposited on formvar-carbon-coated 
nickel grid (150 mes), air dried for 15min, washed 6x with PBS, fixed in 1% 
glutaraldehyde/PBS for 5min and then washed 6x for 2min with stilled water drops.  The 
grid was then transferred to a drop mixture of 4% uranyl acetate and 2% methycellulose 
(in a 1:9 ratio) for 5min.  A paper filter was then used to remove excess solution and the 
sample was air dried for 1hr prior to observation with a JEOL (Peabody, MA) 1400 electron 
microscope at 80 KV.    
 
Protein digestion and label free mass spectrometry analysis 
Samples were processed in three separate batches. For the first batch, EV pellets 
were lysed with the addition of 50µl 0.04% ProteaseMax Surfactant (Promega, Madison 
WI) in 50mM Tris buffer pH 8.2 and vortexed for 1min.  5ul of 110mM DTT (5mM final) 
was then added to reduce disulfide bonds and the samples were heated at 70°C for 10min.  





alkylation with 5µl 120mM IAA (10mM final) and incubated for 30min protected from 
light.  Following alkylation an additional 0.675µl of 1.0% ProteaseMax was added prior to 
the addition of 0.1µg of Trypsin LysC mix.  The samples were then vortexed and incubated 
at 37°C for 16hr.  Finally, the digestion was terminated by adding 5µl of 5.25% TFA. 
Sample batches two and three were processed with an optimized method to yield deeper 
proteome coverage.  For these samples, EV pellets were precipitated with the addition of 
50µl of methanol. The methanol was then evaporated in a SpeedVac (Thermo Scientific, 
Waltham MA) and protein was reconstituted with 50µl of 50mM Tris pH 8.2 containing 
0.002% zwittergent Z3-16 (EMD Millipore, Burlington MA) and subsequently heated at 
95°C for 10min. All additional steps are the same as described above except ProteaseMax 
wan not added before the digestion. 
 
LC-MS conditions 
Digested samples (15µl) were loaded onto a 0.33μl OptiPak trap column (Optimize 
Technologies) packed with Halo C18 peptide ES stationary phase.  The trap was then 
washed with an aqueous loading buffer composed of 0.2% FA and 0.05% TFA for 4 
minutes at 10μl/min.  After the wash, the 10-port valve was switched and peptides were 
flushed off of the trap onto a 25cm x 75µm PicoFrit (New Objective) analytical column 
packed with Waters BEH 1.7µm stationary phase using a Dionex UltiMate 3000 RSLC 
liquid chromatography (LC) system (Thermo Scientific).  The analytical gradient for 
peptide separation began at 2% mobile phase B (MPB) and 98% mobile phase A (MPA) 





increased to 95% over 10min, held for 2min, returned to 2% B in one minute and 
equilibrated for 15min.  MPA was composed of 98:2 (water/acetonitrile) with 0.2% FA 
and MPB was composed of 80:10:10 (acetonitrile/ isopropyl alcohol/water) with 0.2% FA. 
Analysis of the eluting peptides was performed using an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Scientific) operated in data dependent mode.  Survey scans were 
acquired from 300-1400m/z with 120,000 resolving power and an AGC of 4e5 and max 
fill time of 50ms.  MS/MS scans of selected precursor ions were performed for a maximum 
of 3s or until the list was exhausted and dynamic exclusion was set to 45s.  Quadrupole 
isolation for MS/MS scans was set at 0.7 m/z followed by fragmentation in the ion trap 
with “Rapid” scan speed and an ion target value of 5e4 and maximum injection time of 
22ms using normalized collision energy of 28% from 200-1200 m/z.  The monoisotopic 
precursor selection was set to peptide and charge states of 1, greater than 5, or unknown 
were excluded.   
 
Quantitation and statistics 
MS raw files were processed in MaxQuant software version 1.6.7.0 (62).  Peptides 
were searched using the Andromeda search engine against the human Uniprot FASTA 
database downloaded July 24th, 2019.  Cysteine carbamidomethylation was set as a fixed 
modification and N-terminal acetylation and methionine oxidations were set as variable 
modifications.  Searches were performed with a false discovery rate of 1% for both peptides 
and proteins using a target-decoy approach.  A minimum of two peptides were required, 





Match between runs was enabled with a retention time window of 0.7min.  Enzyme 
specificity was set to trypsin and a maximum of 2 missed cleavages were allowed.  Protein 
data was extracted from the “proteinGroups.txt” file and differential quantitation was 
carried out in Perseus version 1.6.0.7 (63). Aerobic exercise samples were processed in 
three separate batches and protein quantification results were merged by gene name prior 
to statistical analysis. All other mass spectrometry data was processed using custom R 
scripts. 
For all exercise data, a minimum of 60% non-zero values were required in the post 
exercise group and the protein intensities were log2 transformed. The data was assessed for 
normality and the Pre vs Post exercise data were analyzed with a paired, two sample T test 
with the S0 parameter set to 0.1 and a permutation based FDR threshold of P < 0.05 was 
applied to the data set. 
MS raw files from the cell culture experiments and PPP vs PRP comparisonwere 
searched as described above. Method comparison and SEC fractionation  experiment MS 
raw files searched against the human SwissProt FASTA database downloaded February 
2017, all other parameters are as described above,  Proteomics, nFLC and NTA time course 
analysis measurements of total EV abundance were analyzed using a one tailed two sample 
T test and data is displayed as mean ± SEM.  Plasma concentrations obtained from the 
plasma proteome database for EV enriched proteins and contaminants were compared 
using the Mann-Whitney U test.  All other comparisons were performed using a two tailed 






Pathway and functional enrichment analysis 
Functional annotation enrichment analysis was carried out using DAVID 
Bioinformatics Resources functional annotation tool (v6.8).  Enrichment p values were 
FDR corrected using Benjamimi-Hochberg procedure and gene sets with a p value ≤ 0.05 
were reported.  Proteins that were statistically up or down regulated after exercise were 
subjected to Ingenuity Pathway Analysis (IPA) and regulated canonical pathways with a -
log(p-value) ≥ 1.3 and a non-zero z-score were reported.  For cell culture experiments, 
proteins identified uniquely in each cell type were subjected to an overrepresentation 
enrichment analyzed (ORA) using WEBGESTALT software.  Redundancy of enriched 
gene sets was then reduced with the affinity propagation method using the R package 







Chapter 3: Multi-omics analysis of exercise resistance in obese individuals 
 
Introduction 
Obese individuals suffer from derangements in skeletal muscle, including 
mitochondrial impairments, oxidative stress, insulin resistance, and reduced myocellular 
quality. As skeletal muscle is the primary site of macronutrient metabolism, a process that 
is dysregulated in obese individuals, improving the quality of skeletal muscle is an 
important consideration in the treatment of obesity. At present, obesity accounts for 39% 
of adult Americans (64) and is defined as having body mass index (BMI) of 30 or higher. 
Obesity is a known risk factor for several pathologic conditions such as type 2 diabetes, 
cancer, cardiovascular disease and mental illness among others (65,66). If current trends 
continue, nearly half of US adults will be obese by 2030(67), which would drastically 
increase the annual obesity related healthcare costs that have already been estimated at 
more than 190 billion (68).  
Similar to aged individuals, it appears that muscle of obese individuals is resistant 
to the anabolic action of resistance exercise regimes as well as protein ingestion in 
comparison to normal weight adults (12,69). This so called anabolic, or exercise resistance 
leads to impaired muscle protein synthesis which contributes to poor muscle health in 
obesity. The underlying cause of exercise resistance is likely related to insulin resistance, 
intramuscular/systemic inflammation, or lipid accumulation (70), however, the precise 
molecular mechanisms underpinning this phenomenon are not currently understood. To 





resistance in obesity, we performed a quantitative multi-omics comparison of the 
transcriptome, proteome and phosphoproteome in muscle tissue from lean and obese 
individuals before and after and acute bout of aerobic exercise. The aim of our study was 
to identify dysregulated pathways and find potential therapeutic targets that could help 
enhance the benefits of exercise in obese patients with exercise resistance. 
Results 
Quantitative multi-omics analysis of lean and obese subjects. To identify 
baseline differences, and differences in responsiveness to exercise between lean and obese 
subjects we recruited 8 individuals (obese, n = 4; lean, n = 4) to perform one bout of cycling 
at 70% Vo2max using only the left leg. For baseline comparisons, muscle biopsies were 
obtained from the right v. lateralis one day prior to the acute exercise bout. To determine 
how the single bout of exercise regulated exercise-responsive genes we collected post-
exercise muscle biopsies 3hr following exercise. We then carried out a multiplexed 
quantitative proteomics and phosphoproteomics analysis in addition to transcriptome 
profiling of the muscle biopsy samples to investigate systems level regulation of exercise 
related signaling pathways in the lean and obese individuals at the two timepoints. To 
perform the proteome analysis, protein was extracted from muscle tissue, digested with 
trypsin and labeled with tandem mass tags (TMT). The labeled peptides were then 
fractionated and analyzed by nano-LC-MS/MS on an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Scientific, San Jose CA). After filtering decoy sequences and 
common contaminants, 4981 proteins were identified and 9979 phosphosites were 





< 0.05, log2(fold-change) > ±0.5) in obese individuals relative to lean (Figure 12A). At 
 
Figure 12: Baseline changes between obese and lean individuals. (A-C) Volcano plots illustrating 
differences in protein (A), mRNA (B) and phosphopeptide (C) abundance between obese and lean 
individuals. The x-axis indicates the log2(fold-change) and the y-axis indicates the significance (-
log10(FDR)). Positive log2(fold-change) indicates increased abundance in obese individuals. Changes 
with a higher significance than the maximum value on the y-axis are plotted at the max value (D) 
Enriched gene sets from the baseline mRNA and protein differential comparison identified by gene set 
enrichment analysis (GSEA) are displayed in a heatmap. Coloring represents the normalized enrichment 





the phosphorylation level, 139 phosphosites were  
upregulated and 51 were downregulated in obese subjects relative to lean controls using 
the same significance thresholds (Figure 12C). Interestingly, the majority of 
phosphorylated peptides were not regulated at the protein level, suggesting that 
phosphorylation signaling is altered in the obese subjects (data not shown). At the mRNA 
level, 13175 transcripts were identified of which 97 were upregulated and 65 were 
downregulated in obese subjects relative to lean controls (Figure 12B). In total, 
quantitative measurements were obtained for 27679 molecules. 
To investigate systems level pathway alterations in the obese subjects we identified 
enriched gene sets in the proteomics and transcript data using gene set enrichment analysis 
(GSEA) and merged the results in a heatmap (Figure 12D). As expected, gene sets related 
to mitochondrial translation and oxidative phosphorylation were negatively enriched in 
obese subjects at the transcriptome and proteome level. Mitochondrial impairments are 
well characterized in the pathogenesis of obesity (71). In addition to mitochondrial 
impairments, decreased muscle protein synthesis is thought to play a role in impaired 
muscle function and quality in obese individuals (69). In line with previous reports, 
signatures of reduced protein synthesis were identified in obese subjects at the transcript, 
but not protein level. Interestingly, several proteins involved in protein translation 
including  EIF4G3, EIF2B5, EIF4A2 and EIF4G1were upregulated in obese subjects, 
raising the possibility that increased stability of these proteins could be a compensation for 






Next, we examined phosphosite-centric kinase activity enrichment using PTM-
SEA (72). This analysis identified the significant regulation (FDR < 0.1) of several kinases. 
For instance, inferred kinase activities for PAK1, ERK1/MAPK3, GSK3B and PRAKA 
were downregulated in obese subjects while the activities of others such as 
 
Figure 13: Transcriptome changes after exercise in obese and lean individuals. Differences in 
transcript abundance after exercise are displayed in volcano plots for lean (A) and obese (B) individuals. 
The x-axis indicates the log2(fold-change) and the y-axis indicates the significance (-log10(FDR)). 
Positive log2(fold-change) indicates an increase in transcript abundance after exercise. (C) Transcripts 
which are upregulated (left) and downregulated (right) after exercise are compared between obese and 
lean individuals with a Venn-diagram. (D) Transcripts significantly altered after exercise are clustered 
and displayed in a heatmap. (Left) Transcripts altered by exercise in lean individuals are displayed with 
the corresponding changes in obese individuals to illustrate differences in the response to exercise 
between the two groups. (Right) Transcripts significantly altered in obese individuals are shown with 






p90RSK/RPS6KA1, PLK1, AKT1, PKCA/PRKCA and CDK1 were upregulated (Figure 
15D). 
Lean and obese subjects display different responses to exercise. To characterize 
differences in the molecular response to exercise between the lean and obese subjects, we 
performed a differential analysis comparing the post-exercise timepoint to the pre-exercise 
timepoint for each group. The response to exercise at the transcript level was markedly 
different between groups. In the lean group, 419 transcripts were upregulated and 132 were 
downregulated after exercise with an adjusted p-value < 0.05 and log fold-change > ± 0.5 
(Figure 13 A-C). In contrast, only 82 transcripts were increased and 22 were decreased 
after exercise in the obese group and minimal overlap resulted unique responses in each 
group (Figure 13D). Unique responses to exercise in each group were also observed at the 
protein level where the upregulation of 68 proteins and downregulation of 18 proteins was 
observed in lean group (Figure 14 A-C). In comparison only 20 proteins were upregulated 
in the obese group whereas 40 were downregulated leading to distinct responses within 
each group (Figure 14E). To study systems level regulation we again performed gene-
centric pathway enrichment using GSEA and merged transcript and protein results in a 
heatmap to visualize coordinated pathway changes (Figure 14D). At the transcript level, 
multiple gene sets were significantly regulated in the lean group. This includes the 
downregulation of multiple gene sets related to mitochondrial translation and oxidative 
phosphorylation. Additionally, several gene sets were enriched after exercise in the lean 
group including signaling by receptor tyrosine kinases. None of these pathways, however, 





and the timepoint at which the post exercise sample was collected and suggests that protein 
level changes had not occurred by 3hr post exercise. Interestingly, in contrast to the lean 
group no regulated gene sets were identified at the transcript level in the obese group, 
however, multiple gene sets were regulated at the protein level. Regulated pathways at the 
protein level include downregulation of multiple gene sets related protein translation 
including ribosome and eukaryotic translation initiation. Multiple upregulated gene sets 
 
Figure 14: Proteome changes after exercise in obese and lean individuals. Exercise induced changes 
in protein abundance are displayed in volcano plots for lean (A) and obese (B) individuals. The x-axis 
indicates the log2(fold-change) and the y-axis indicates the -log10 value of the false discovery rate (FDR). 
Positive log2(fold-change) indicates an increased protein abundance after exercise. (C) Proteins which 
are upregulated (left) and downregulated (right) after exercise are compared between obese and lean 
individuals in a Venn-diagram. (D) Enriched gene sets identified in the transcript and protein exercise 
comparison are displayed in a heatmap to illustrate pathway regulation at a systems level. Color 
represents normalized enrichment score, all significant changes (adjusted p-value < 0.05) are indicated 
with an asterisk. (E) Proteins significantly altered after exercise are clustered and displayed in a heatmap. 
(Left) Proteins altered by exercise in lean individuals are displayed with the corresponding changes in 
obese individuals to illustrate differences in the response to exercise between the two groups. (Right) 







after exercise in the obese group were related to proteasomal degradation including 
proteasome antigen processing and cross presentation. Previous reports have demonstrated 
alteration in the ubiquitin proteasome system (UPS) in obesity and insulin resistance, but 
the effect of exercise on the UPS in muscle has not been studied. Insulin resistance 
increased degradation of muscle protein through a mechanism which involves suppression 
of PI3K/AKT signaling and activation of the UPS (73). Additionally, skeletal muscle cells 
from obese donors display elevated proteasomal activity and decreased flux through the 
autophagic/lysosomal pathway (74). Our findings, together with previous reports suggest 
that reduced protein synthesis together with increased proteasomal activity after exercise 
in obese subjects may contribute to poor muscle tissue maintenance and reduced muscle 
quality.    
We next evaluated differences in regulation of phosphorylation after exercise in the 
lean and obese groups. Differential analysis of the pre- and post-exercise timepoints 
identified upregulation of 229 phosphosites after exercise while 25 were downregulated. 
Similar to the transcript and protein level, obese subjects displayed a markedly different 
response to exercise at the phosphorylation level. After exercise, only 56 phosphosites were 
upregulated in the obese group whereas 44 were downregulated (Figure 15 A-C). Minimal 
overlap of regulated phosphosites suggests that the lean and obese groups have unique 
alteration in phosphorylation after exercise (Figure 15C). To identify regulated signaling 
pathways and kinase activity after exercise in each group we again utilized PTM-SEA 
(Figure 15D). This analysis identified increased activity of 4 kinases after exercise in the 





were significantly increased after exercise in the obese group. In the obese group, activity 
of PLK1 was increased after exercise. Interestingly, the activity of CK2A1 (casein kinase 
2) was upregulated after exercise in the obese group and downregulated after exercise in 
the lean group. Interestingly, previous reports have shown that CK2 activity inhibits the 
 
Figure 15: Phosphoproteome changes after exercise in obese and lean individuals. Exercise induced 
changes in phosphorylation are displayed in volcano plots for lean (A) and obese (B) individuals. The x-
axis indicates the log2(fold-change) and the y-axis indicates the -log10 value of the false discovery rate 
(FDR). Positive log2(fold-change) indicates an increased protein abundance after exercise. (C) 
Phosphopeptides which are upregulated (left) and downregulated (right) after exercise are compared 
between obese and lean individuals in a Venn-diagram. (D) Enriched phosphorylation signatures 
obtained from PTM-signature enriched enrichment analysis (PTM-SEA) are displayed in a heatmap to 
illustrate regulation of signaling pathways. Enriched phosphorylation signatures identified from the 
baseline comparison of lean and obese individuals are displayed (left) next to enriched phosphorylation 
signatures after exercise in lean (center) and obese (right) individuals. Color represents normalized 
enrichment score, all significant changes (adjusted p-value < 0.05) are indicated with an asterisk. (E) 
Sequences logos for enriched phosphorylation motifs identified in exercise induced changes from lean 
individuals using the Motif-X algorithm are displayed. (D) Proteins significantly altered after exercise 
are clustered and displayed in a heatmap. (Left) Proteins altered by exercise in lean individuals are 
displayed with the corresponding changes in obese individuals to illustrate differences in the response to 
exercise between the two groups. (Right) Proteins significantly altered in obese individuals are shown 










storage depots, whereas brown adipocytes are metabolically active and produce heat via 
 
Figure 16: Integrated multi-omics network analysis identifies altered network modules in obese 
individuals. Transcriptome, proteome and phosphoproteome data was z-transformed and merged into a 
single matrix for weighted correlation network analysis (WCGNA) to identify modules of co-regulated 
molecules that associate with phenotypic traits. (A,B) The two most significant positively and negatively 
correlated network modules associated with obesity status (“Exercise Static”, A) and obesity status and 
exercise (“Exercise Dynamic”, B) are plotted in a heat map and separated by module (rows) and sample 
group (columns). Molecule type (i.e. mRNA, protein or phosphopeptide) is color-coded as indicated by 
the bar on the right. (C) Summary of enriched pathways in exercise static or exercise dynamic network 
modules. A two-sided hypergeometric test was performed to obtain p-values, and correction was carried 
out with Bonferroni step down. A significance threshold of adjusted p-value = 0.05 was applied and 
significant pathways are indicated by color. Significant exercise static pathways are colored red, 
significant exercise dynamic pathways are blue. (D) Figure representing enriched pathways from the 





mitochondrial uncoupling. Beige adipocytes are thought to be white adipocytes that 
respond to stimuli and share properties more similar to brown adipocytes (75). The 
observation that CK2A1 is downregulated after exercise in lean, but upregulated in obese 
suggests dysregulated brown adipocyte formation in obese individuals may be related to 
altered CK2 signaling in muscle tissue after physical activity. Although these findings are 
promising, further experiments are required to fully characterize the biological significance 
of CK2 signaling in muscle after exercise. 
Integrative Multi-omics analysis identifies clusters of molecules associated 
with the obese phenotype and differential responses to exercise. Next, we leveraged the 
multi-omics data to identify clusters of molecules associated with obesity status and 
exercise timepoints. Towards this goal the proteome, phosphoproteome and transcriptome 
data were transformed to the same scale and merged prior to weighted gene co-expression 
network analysis (WCGNA) (76,77). WCGNA identified 100 functional modules. The 
four modules most significantly correlated with obesity status (Figure 16A) and exercise 
time point (Figure 16B) were then subjected to functional enrichment analysis in ClueGo 
(Figure 16C). As modules associated with obesity status did not change with exercise, they 
were termed “exercise static” (ES), whereas modules associated with exercise timepoint 
were termed “exercise dynamic” (ED). Each exercise refractory and exercise dynamic 
module had varying molecular composition. For instance, exercise refractory module 1 was 
composed primarily of mRNA and was significantly enriched (adj.p-value < 0.05) for 
molecules involved in pathways such as ubiquitin mediated proteolysis, autophagy, and 





lean. Exercise refractory module 2 was driven by a high percentage of phospho peptides 
that associated with pathways such as glycolysis/gluconeogenesis, HIF-1 signaling, and 
glucagon signaling, which were also increased in obese individuals. Exercise responsive 
molecules also displayed varying molecular composition. Exercise responsive module 2 
 
Figure 17: Network analysis of kinases, phosphatases and transcription factors reveals 
dysregulation of signaling networks in obese individuals. Kinase and phosphatase transcripts, proteins 
and phosphopeptides with significant network module phenotype associations were clustered to identify 
alterations in signaling molecules that associate with obesity and the response to exercise. Kinase and 
phosphatase transcripts, proteins and phosphopeptides that associate with obesity status (A), exercise 
status (B) or obesity status and exercise are displayed in a heatmap. Molecules in each heatmap were 
filtered by module p-value in order to display row labels. The color or each row represents z-score. The 
molecule class is color coded as indicated by the car on the right. Transcription factor transcripts, proteins 
and phosphopeptides that are significantly associated with obesity status (C), exercise status (D), or 
obesity and exercise (E) are displayed in a heatmap. Molecule class is as indicated by the color coded 






was composed of primarily protein and 
phosphopeptides which were significantly enriched for molecules involved in processes 
such as long term potentiation, tight junctions and neurotrophin signaling (Figure 16B,D).  
Figure 18. Pathway based 
quantitative data integration of 
exercise induced changes in lean 
and obese subjects. Differential 
expression analysis of transcript, 
phosphorylation and protein level 
data are overlaid on the Kegg 
insulin signaling pathway. 
Molecules with significant changes 
after exercise (adjusted p-value < 
0.05 and log2 fold change > 0.5) are 
colored according to their log2 fold 
change. Post/Pre exercise changes 
for lean individuals are indicated 
on the top graph, whereas 
Post/Pre exercise changes for 
obese individuals are indicated on 
the bottom graph. Functionally 
characterized phosphosites are 
indicated by black text and 
phosphosites that are currently 
uncharacterized are indicated by 
grey text. Molecular interactions 
are indicated by red(positive 










Lean and obese subjects displayed large differences in phosphorylation after acute 
exercise. Therefore, to further investigate the underlying cause of the differential 
phosphorylation signaling that occurred in lean and obese subjects after exercise we 
clustered all transcripts, proteins and phosphopeptides derived from kinases and 
phosphatases that belonged to modules significantly associated with obesity and exercise 
status by WCGNA. This analysis identified clusters of kinases and phosphates associated 
with obesity status (Figure 17A) exercise timepoint (Figure 17B) and both exercise and 
obesity (Figure 17C). Further, we performed the same analysis for transcription factors 
(Figure 17 D-F). Transcription factors also formed clusters associated with obesity status, 
exercise timepoint and both. Transcription factors are generally present at very low levels, 
therefore, it is not surprising that the clusters were composed primarily of transcripts.     
Dysregulated glycogen synthesis signaling is associated with obesity. 
Integration of multi-omic kinase and phosphatase data using WCGNA uncovered a 
dysregulation of GSK3β signaling in obese subjects. GSK3β mRNA was associated with 
obesity status, where higher levels were observed in obese subjects (Figure 17A). Further 
investigation found that obese subjects also displayed increased phosphorylation of GSK3β 
at S9, a known inactivating phosphorylation event (78). After exercise, phosphorylation of 
S9 increased in both groups, however, GSK3β and GSK3α protein levels increased only in 
the lean group (Figure 17B, 18). GSK3β is a serine/threonine kinase and important 





immune function (79-81). GSK3β phosphorylates and inactivates GYS (82), leading to 
reduced glycogen synthesis. Additionally, after exercise lean individuals displayed 
upregulated PPPR3A mRNA and decreased phosphorylation on S46, a known activating 
phosphorylation whereas obese individuals displayed no change (Figure 18). PPPR3A, 
also known as GM, is a regulatory subunit of protein phosphatase-1 (PP-1) expressed in 
muscle which recruits and positively regulates GYS by dephosphorylation (83). These data 
indicate that exercise induces mRNA, protein and phosphorylation level changes after 
exercise in lean individuals that modulate glycogen synthesis, whereas obese individuals 
do not display the same alterations. Previously,  mice expressing phosphorylation resistant 
GSK3β were shown to be resistant to metabolic disorder characterized by insulin 
resistance, obesity and dyslipidemia through a process which involved GSK3β-dependent 
upregulation of the hormone adiponectin (84). Interestingly, obese subjects in the present 
study also displayed decreased levels of adiponectin relative to lean subjects at baseline. 
Taken together, these data indicate that GSK3β signaling is dysregulated in obese subjects 
which may alter glycogen synthesis and result in reduced muscle quality in obese 
individuals. GSK3β has been evaluated as a therapeutic target in other pathological 
conditions such as cancer (85). Therefore, GSK3β is a potential a point of therapeutic 
intervention in obesity induced muscle derangements and warrants further investigation. 
Although several molecules involved in GSK3β signaling are dysregulated in obese 
subjects in the present study, others have shown that glycogen synthesis is not altered in 
subjects with type II diabetes and obesity after exercise relative to lean individuals (86). 





Western blots are known to un-specific and should be confirmed by more specific 
methodologies such as mass spectrometry. Never the less, these results are discrepant and 
further studies are required to characterize alteration in GSK3β signaling in obese subjects 
after exercise. 
Discussion: 
Obesity is a known risk factor for several chronic conditions, and muscle of obese 
individuals has been shown to have impaired mitochondrial function, reduced protein 
synthesis rates and reduced myocellular quality. In this study, we used a multi-omics 
approach to elucidate molecular aberrations that underlie poor muscle tissue health in obese 
individuals. At baseline, we found signatures of reduced oxidative phosphorylation and 
mitochondrial protein translation using gene centric GSEA (Figure 12, D). In addition, 
GSEA identified reduced levels of protein synthesis in obese individuals, another hallmark 
of exercise resistance in obesity. The identification of known impairments in obese muscle 
in this data set indicate the quality of this data set, and provide confidence that novel 
alterations uncovered in this study are accurate even though a limited number of subjects 
per group were available.  
Relative to lean subjects, obese subjects displayed markedly different responses to 
exercise at the transcript level (Figures 13, A-D) protein level (Figure 14, A-C,E) and 
phosphorylation level (Figure 15, A-C, F). In lean individuals, integrated gene centric 
pathway analysis identified a decrease in mitochondrial translation and oxidative 
phosphorylation at the transcript, but not protein level after exercise. Lean individuals also 





individuals did not. Interestingly, dysregulated receptor tyrosine kinase signaling has been 
implicated in obesity and is the current focus of several research groups (87,88). In obese 
individuals, GSEA identified decreased levels of protein translation together with 
increased proteasomal activity. These findings, suggest that reduced protein synthesis 
together with increased proteasomal activity after exercise in obese subjects may contribute 
to poor muscle tissue maintenance and reduced muscle quality. 
At the phosphorylation level, PTMSEA identified the enrichment of several kinase 
signatures including Erk1/MAPK3, GSK3B and PKCD. Importantly, none of these kinases 
were significantly increased after exercise in the obese group. Additionally, the activity of 
CK2 was decreased after exercise in the lean group whereas its activity was increased after 
exercise in the obese group. In adipose tissue, CK2 has previously been shown to inhibit 
the conversion of white adipocytes to more metabolically active beige adipocytes (75). 
Beige adipocytes are thought to be white adipocytes that respond to stimuli and share 
properties more similar to brown adipocytes (75). Thus, the observation that CK2 is 
downregulated after exercise in lean, but upregulated in obese suggests dysregulated brown 
adipocyte formation in obese individuals may be related to altered CK2 signaling in muscle 
tissue after physical activity. Although the significance of CK2 signaling after exercise in 
lean and obese individuals requires further investigation, this observation suggests that 
dysregulated CK2 signaling may underlie metabolic alterations in obese individuals and 
future studies are warranted.  
Multi-omics integration identified networks of regulated kinases, phosphatases and 





integration of transcript, proteome, and phosphorylation data by WCGNA identified 
dysregulated GSK3β signaling in obese individuals at baseline, and after exercise. Baseline 
comparison of phosphorylation profiles between lean and obese subjects uncovered 
increased phosphorylation of GSK3β as serine-9. After exercise, phosphorylation of 
GSK3β at serine-9 increased in lean and obese individuals, however, 3 phosphosites on 
GYS (serine 641, 645, 649) were reduced in lean individuals but not obese. 
Phosphorylation of GYS inactivates glycogen synthesis, while de-phosphorylation 
increases activity. These data indicate that GYS is inactivated after exercise in obese, but 
not lean. Further two phosphosites on PP-1, the phosphatase that positively regulates GYS 
were increased after exercise in lean, but not obese. Collectively, these alterations indicate 
that GSK3β signaling, and likely glycogen synthesis are dysregulated in obese, relative to 
lean individuals. Previous studies have suggested that glycogen synthesis is not altered in 
obesity (86), however this study utilized western blots to quantify differences in 
phosphorylation of GYS. The fact that multiple levels of GSK3β signaling are regulated in 
this study and considering that we utilized mass spectrometry, a technique with much 
higher specificity relative to western blot, these data warrants further investigation of 
GSK3β signaling in obesity.  
 
Conclusion: 
In this study, we utilized a multi-omics approach to identify systems level 
alterations in obese individuals at baseline and in response to exercise relative to lean 





increases in pathways related to proteasomal degradation, which we hypothesize may cause 
unbalanced myocellular homeostatis and exercise resistance. Obese individuals also 
displayed significant differences in phosphorylation profiles after exercise, and reduced 
kinase activity. Of interest is a reciprocal regulation of CK2 in lean and obese subjects after 
exercise, which may play a role in adipose tissue browning. Finally, we identified 
dysregulated GSK3β signaling in obese individuals after exercise and suggest that future 




RNAseq. RNA was extracted from powdered muscle biopsy samples using the 
Qiagen RNeasy mRNA extraction kit and sent to the Mayo Clinic Genome Analysis Core 
for sequencing. Briefly, libraries were prepared using the Illumina Stranded mRNA Prep 
and sequenced on an Ilumina HiSeq 4000. Reads will be aligned using STAR RNA-seq 
aligner. Differential expression analysis was carried out using a negative binomial 
generalized log-linear model in the edgeR R package.  
 
Protein extraction and digestion 
Muscle samples were powdered and protein was extracted with 8M urea in 100mM 
TEAB containing HALT™ phosphatase inhibitor cocktail (Thermo Scientific, Waltham, 
MA). Samples were then probe sonicated to ensure complete homogenization, and protein 





reduced and alkylated with10mM TCEP and 10mM IAA at RT for 30min while protected 
from light. Trypsin/LysC Mix (Promega, Madison, WI) was added at a 1:50 enzyme to 
protein ratio and samples were digested overnight (16hr) at 37°C.  The enzymatic digest 
was terminated by adding TFA to a final concentration of 0.2% and peptides were desalted 
using a 10mg Strata-x PSVDB cartridge (Phenomenex, Torrance, CA), dried, and 
reconstituted in 100µl of 50mM TEAB. Peptide concentration was determined using a 
Pierce Colorimetric peptide assay and 95µg from each sample was labeled with TMT-Pro 
(Thermo Scientific) for 1hr. 
High pH reversed phase fractionation 
TMT labeled peptides were fractionated by high pH reversed phase liquid 
chromatography on Dionex Ultimate 3000 (Thermo Scientific, Waltham, MA). Peptides 
(1.6 mg) were separated on a 4.6 mm x 50 cm x 3.5µm Xbridge column (Waters, Milford, 
MA) with a 2 h gradient from 2 to 40% B mobile phase B (MPB). MPA was composed of 
20 mM ammonium formate in water and MPB was composed of 20 mM ammonium 
formate in 80% ACN.  A total of 96 fractions were collected and concatenated into 48 
fractions.  A 20 µg equivalent of each fraction was set aside for global proteome analysis 
and the rest of each sample was concentrated into 24 fractions and dried prior to 
phosphopeptide enrichment. 
Phosphopeptide enrichment 
Each fraction was reconstituted in 100 µl of 80% ACN in 0.1% TFA and transferred 





NTA resin (G5496-60082) on an AssayMap Bravo (Agilent Technologies, Santa Clara, 
CA) platform  following the manufacture instruction. 
LC-MS/MS analysis 
Fractionated, TMT labeled peptides (5µg) were loaded onto a 20 mm x 0.075 mm 
PepMap C18 trap column with loading solvent composed of 0.1% TFA flowing at 20 
µl/min using an Ultimate 3000 nano HPLC (Thermo Scientific, Waltham, MA).  After 4 
minutes, the 10-port valve was switched and peptides were eluted off the trap column onto 
a 50 cm x 75 µm ID PepMap EASY-Spray™ analytical column and peptides were 
separated with a 2 hr gradient from 3 to 40% mobile phase B (MPB). At 2 hr, MPB was 
increased to 80% over 10 min, held for 15 min, and then returned to 3% for 5 minutes to 
re-equilibrate the column. The flowrate was set to 300 nl/min. Eluting peptides were 
analyzed on an Orbitrap Fusion Lumos (Thermo Scientific, Waltham, MA) mass 
spectrometer operated in data dependent mode. MS1 scans were acquired from 370-1700 
m/z with an orbitrap resolution of 60,000 (at 200 m/z) at least every three seconds or when 
no more peptides were scheduled for fragmentation. The automatic gain control (AGC) 
was set at 1e6 and maximum ion fill time was set to 50 ms. The most abundant peptides 
with a charge state between 2 and 7 were selected for fragmentation with high-energy 
collision induced dissociation (HCD) using a normalized collision energy of 35% and a 
quadrupole isolation width of 0.7 m/z. The orbitrap resolution was set to 30,000, the 
maximum injection time was set to 54 ms, and the AGC target was set to 2e5 whereas the 





analysis, the resolution for MS/MS was set to 50,000 and the maximum injection time was 
set to 86 ms. 
Data Analysis 
MS raw files were processed in MaxQuant software version 1.6.12 (62).  Peptides 
were searched using the Andromeda search engine against the human Uniprot FASTA 
database downloaded July 24th, 2019.  Cysteine carbamidomethylation was set as a fixed 
modification and N-terminal acetylation, methionine oxidation and phosphorylated serine, 
threonine and tyrosine were set as variable modifications.  Searches were performed with 
a false discovery rate of 1% for both peptides and proteins using a target-decoy approach.  
Peptide length was to at least 7 amino acids long and MS2 match tolerance was set to 
0.02Da.  Enzyme specificity was set to trypsin and a maximum of 2 missed cleavages were 
allowed.  Protein data was extracted from the “proteinGroups.txt” file and differential 
quantitation was carried using a generalized linear model as previously described (56). 
Gene Set Enrichment Analysis 
Gene set enrichment analysis was performed using Broads GSEA software. All 
gene sets that were negatively enriched with an FDR corrected p-value (using the 
Benjamini-Hochberg procedure) < 0.05 were reported. Phosphorylation site specific 
signature analysis was performed using PTM signature enrichment analysis (PTM-SEA) 
(89) with PTMSigDB version 1.9.0. All perturbation signatures, signature sets of molecular 
signaling pathways, kinase substrate signatures and disease-associated signature sets with 






The transcript, proteome and phosphoproteome data were z-transformed, merged 
and analyzed by WCGNA (77). Briefly, a Pearson correlation matrix was calculated and 
both positive and negative correlations were accepted. Eigen genes were calculated as a 
consensus trend for each module and additional molecules were assigned based on Pearson 
correlation values. The four modules most significantly correlated with obesity status and 
exercise timepoint were subjected to gene level pathway analysis in CludGO (90). Pathway 
analysis in ClueGo was performed using a two-sided hypergeometric test using information 
obtained from Kegg. All pathways with a Bonferroni step down adjusted p-value < 0.05 
were accepted. To identify networks of regulated molecules that affect phosphorylation 
signaling all kinases and phosphatases assigned to network modules with a significant 
association to obesity status or exercise timepoint were selected and subjected to 
hierarchical clustering. Networks of regulated transcription factors were identified using 






Chapter 4: Extracellular Vesicles as Markers of Disease Biology in Multiple Myeloma 
 
Introduction: 
Multiple myeloma (MM) is a devastating clonal plasma cell proliferative disorder 
responsible for over 13,000 deaths per year in the US. MM is always preceded by a pre-
malignant condition termed monoclonal gammopathy of undetermined significance 
(MGUS) or a more advanced pre-malignant stage termed smoldering multiple myeloma 
(SMM). Patients with both MGUS and SMM require continuous clinical monitoring to 
assess for the development of malignant plasma cells (PCs) which result in the progression 
to MM. At present, no single clinical or laboratory feature can distinguish between the 
presence of premalignant (MGUS or SMM) or malignant clonal plasma cells (MM). As a 
result, MGUS and SMM patients who have already started to develop malignant clonal 
PCs progress to MM in between their scheduled clinical monitoring visits with organ 
damage such as lytic bone disease and/or renal insufficiency that adversely affects their 
survival. Thus, novel biomarkers which reflect the presence of malignant clonal plasma 
cells are needed to identify patients with pre-malignant disorders such as MGUS and SMM 
destined to rapidly progress to MM.  
 
At a molecular level, premalignant and malignant plasma cells are 
undistinguishable (91). Furthermore, the genetic and epigenetic aberrations which are 
necessary for the transformation of normal to malignant plasma cells are largely present in 





the bone marrow micro environment (BMM) and its role in disease progression (20,21) in 
the setting of MM. It is now well established that alterations in the BMM facilitate tumor 
growth, angiogenesis bone disease and immune evasion (20-22) which promote disease 
progression. The exchange of soluble factors including cytokines,  growth factors and 
extracellular vesicles (EVs) facilitate intercellular communication between myeloma and 
non-myeloma cells and are now recognized as a major determinant in disease response and 
progression (22,92).  
 
Results and Discussion: 
Although advances in our understanding of MM disease biology are promising, 
there is still a need for improved tests which can monitor disease progression and predict 
which patients will rapidly progress to malignant disease. Extracellular vesicles (EVs), 
including exosomes (SEVs) and microvesicles (LEVs) have received attention for 
facilitating intercellular communication and may be involved in supporting disease 
progression by mediating cross talk between tumor cells and the surrounding 
microenvironment. It has also been suggested that plasma derived EVs may serve as a 
reservoir of potential biomarkers that can shed light on disease biology in MM has. Until 
recently, however, technical factors including abundant plasma protein contamination and 
low EV recovery have precluded useful mass spectrometry-based profiling studies of 
plasma derived EVs (30). Here, we used a size exclusion chromatography based EV 
isolation method coupled to a label-free proteomics workflow to compare protein 





MM. The results of this comparison indicate that EVs may indeed be a useful reservoir of 
biomarkers in the setting of MM.  
 
Using the SEC based method, we isolated SEVs and LEVs from the plasma of 
MGUS (n=10) and MM (n=11) patients. In total, 2055 proteins were identified in SEVs 
while 2794 proteins were identified in LEVs (Figure 1A). While many proteins were 
identified commonly between the two populations of EVs, some were unique to each 
subtype (LEVs = 1171, SEVs = 432), indicating that these are two distinct populations of 
 
Figure 19. Differential comparison of protein composition and abundance between subjects with 
MM and MGUS in SEVs and LEVs. (A) Bar chart displaying the total number of proteins identified 
in SEVs and LEVs. (B) Venn diagram displaying the distribution of identified proteins in LEVs and 
SEVs. (C) Volcano plot illustrating differentially expressed proteins in MM relative to MGUS in SEVs 
and LEVs (D). positive fold change indicates increased abundance in MM. (E) Cartoon illustrating the 





vesicles. Within the SEVs, a differential comparison of protein abundance between MGUS 
and MM patients identified 6 upregulated and 2 downregulated proteins in MM relative to 
the MGUS group. Similarly, a differential comparison within the LEVs identified three 
upregulated proteins in the MM group relative to the MGUS group.  
 
Interestingly, transferrin receptor (CD71) was upregulated in MM patients in both 
populations of EVs. CD71 is a cell surface receptor which facilities cellular iron uptake 
through receptor mediated endocytosis (93). In general, CD71 has a low level of expression 
on normal cells, however it’s expression is dramatically increased in a wide variety of 
cancers (93,94). Anemia is also a common complication in patients with MM. A study 
utilizing the VK*MYC murine model of MM found high levels of CD71 expression on 
PCs and iron accumulation in BM macrophages, suggesting that a local depravation of iron 
in the BMM may lead to anemia (95). These lines of evidence suggest that PC CD71 may 
be shed in EVs (Figure 1E) and increased levels could potentially be associated with 
increased disease burden. However, future studies which systematically investigate this 
link are required. 
 
Three isoforms of serum amyloid A, SAA1, SAA2 and SAA4 were also highly 
upregulated in SEVs within MM patients relative to MGUS patients (Figure 1 C). SAA 
acute phase proteins are primarily expressed in the liver and are regulated by pro-
inflammatory cytokines, however, its expression has also been observed in several primary 





and has clinical utility as a marker of inflammation (97). Recent work has shown that SEV 
derived SAA levels are increased in pediatric subjects with anaplastic lymphoma kinase 
(ALK)-positive anaplastic large-cell lymphoma (ALCL) relative to healthy controls (98). 
Therefore, increased SAA levels in SEVs are associated with malignant disease and 
represent a potential biomarker of multiple hematological malignancies. 
 
Next, we investigated associations between cytogenetic abnormalities and EV 
protein abundance by performing a differential comparison between MM patients with 
standard and high cytogenetic risk. This comparison uncovered a clear trend of decreased 
EV protein abundance in patients with high cytogenetic risk relative to those with standard 
risk. Within the SEVs, a total of 73 proteins were downregulated in high cytogenetic risk 
relative to standard risk (Figure 2A). Similarly, 13 proteins were downregulated in high 
risk relative to standard risk within the LEVS, while only three proteins were upregulated 
(Figure 2B). Cytogenetic risk groups also separate into distinct clusters (Figure 2C,D) 
despite displaying moderate inter-subject variability (Figure 2E,F) Interestingly, gene 
ontology over-representation analysis of the proteins downregulated in SEVs identified 
several enriched biological processes including positive regulation of immune response to 
tumor cells, leukocyte degranulation, chemotaxis and regulation of immune system process 
(Figure 2G) suggesting that a more functional immune response may be associated with 
decreased cytogenetic risk. Previous studies have shown that subjects with high risk SMM 





adaptive immune response function has not been studied between high and standard 
cytogenetic risk.  
 
 
Figure 20. Differential comparison of protein composition and abundance in abundance between 
subjects with high and standard cytogenetic risk. Volcano plot illustrating differentially expressed 
proteins in high cytogenetic risk subjects relative to subjects with standard cytogenetic risk in SEVs (A) 
and LEVs (B). Multidimensional scaling (MDS) plot illustrating the distance between subjects with high 
and standard cytogenetic risk in SEVs (C) and LEVs (D). Heatmap illustrating inter-subject variability 
within differentially expressed proteins in SEVs (E) and LEVs (F). Bar plot illustrating significantly 
overrepresented biological processes in proteins down regulated within SEVs in subjects with high 
cytogenetic risk relative to standard risk. (H) Bar plot illustrating the average protein intensity of CD40 






Within the LEVs, CD40 was exclusively identified in subjects with standard 
cytogenetic risk. Interestingly, CD40 was also upregulated in MM relative to MGUS 
patients. Taken together, these data indicate that CD40 expression is increased in subjects 
with standard cytogenetic risk  
MM relative to MGUS, however, its expression is below detectable limits or lost in 
subjects with high cytogenetic risk (Figure 2H). CD40 is a co-stimulatory receptor 
expressed on the surface of B cells and professional antigen-presenting cells which is 
required for their activation. CD40 engagement by its ligand CD40L on activated T cells 
regulates a diverse set of cellular processes including cellular and humoral adaptive 
immunity (100). The observation that CD40 was not detected in high risk subjects 




The results of this study demonstrate that plasma EVs have the potential to serve 
as biomarkers of disease biology in MM. We have shown that CD71 present on SEVs and 
LEVs is upregulated in patients with MM relative to MGUS. This finding may have 
diagnostic importance and future studies which focus on the origin of this signal may shed 
light on mechanisms involved in progression from pre-malignant to malignant disease. We 
have also demonstrated that a diverse set of proteins are downregulated in EVs derived 
from high cytogenetic risk MM patients relative to MM patients with standard risk. In 





immune dysregulation may be associated with high cytogenetic risk. Finally, we have 
shown that LEV derived CD40 is upregulated in subjects with MM relative to MGUS, but 
only in those with standard cytogenetic risk. CD40 was not detected in MM patients with 
high cytogenetic risk, suggesting that impaired adaptive immune function is correlated with 
high cytogenetic risk. We suggest that EVs may provide diagnostic value in MM and future 
studies validating these findings are warranted. 
Methods  
Blood collection and plasma preparation 
Whole blood was drawn into ETDA tubes and placed on the benchtop for 
15minutes.  After 15minutes each tube was centrifuged at 2,000xg for 10min at room 
temperature (RT) to pellet red blood cells.  The upper plasma fraction was then collected, 
transferred to a new sterile tube, and centrifuged again at RT for 10min at 2000xg.  Platelet 
poor plasma was isolated by carefully transferring the top layer of plasma to a new tube 
and then frozen at -80°C in 1ml aliquots. 
 
Isolation of plasma extracellular vesicles by size exclusion chromatography (SEC) 
Frozen platelet poor plasma was removed from the freezer, thawed on ice and 
centrifuged at 2,000xg for 10 min to pellet debris.  The plasma was then transferred to a 
new microcentrifuge tube and centrifuged at 10,000xg for 10min to pellet larger vesicles.  





analysis.  Extracellular vesicle isolation was performed using a qEV 2.0 size exclusion 
chromatography column (Izon Science, Christchurch, New Zealand) following the 
manufactures protocol.  Briefly, SEC columns were equilibrated to room temperature and 
flushed with 90ml of phosphate buffered saline (PBS) before use.  Platelet poor plasma 
(time course analysis: 1.2ml, all other experiments: 2.0ml) was transferred into the sample 
loading reservoir of the SEC column.  The column cap was then removed and the plasma 
sample was allowed to completely enter the column, at which point the sample loading 
reservoir was filled with PBS.  The first 13ml of PBS fraction was discarded and the 
following 8ml’s of EV containing fraction were collected for each sample.  The SEC 
columns were then flushed with 90ml of PBS before the addition of the next sample.  The 
8ml of EV containing fraction for each sample was then pelleted by ultracentrifugation at 
20,000 x g to pellet LEVs. The supernatant was then transferred to a new 
ultracentrifugation tube and SEVs were pelleted at 100,000xg for 1.5hr at 4°C.  Following 
ultracentrifugation the supernatant was discarded and all residual PBS was removed before 
tryptic digestion. 
Protein digestion and label free mass spectrometry analysis 
EV pellets were precipitated with the addition of 50µl of methanol. The methanol 
was then evaporated in a SpeedVac (Thermo Scientific, Waltham MA) and protein was 
reconstituted with 50µl of 50mM Tris pH 8.2 containing 0.002% zwittergent Z3-16 (EMD 
Millipore, Burlington MA) and subsequently heated at 95°C for 10min.  5ul of 110mM 





at 70°C for 10min.  Samples were then equilibrated back to room temperature over 20 
minutes before alkylation with 5µl 120mM IAA (10mM final) and incubated for 30min 
protected from light.  Following alkylation 0.1µg of Trypsin LysC mix was added, the 
samples were vortexed and then incubated at 37°C for 16hr.  Finally, the digestion was 
terminated by adding 5µl of 5.25% TFA.  
LC-MS conditions 
Digested samples (15µl) were loaded onto a 0.33μl OptiPak trap column (Optimize 
Technologies) packed with Halo C18 peptide ES stationary phase.  The trap was then 
washed with an aqueous loading buffer composed of 0.2% FA and 0.05% TFA for 4 
minutes at 10μl/min.  After the wash, the 10-port valve was switched and peptides were 
flushed off of the trap onto a 25cm x 75µm PicoFrit (New Objective) analytical column 
packed with Waters BEH 1.7µm stationary phase using a Dionex UltiMate 3000 RSLC 
liquid chromatography (LC) system (Thermo Scientific).  The analytical gradient for 
peptide separation began at 2% mobile phase B (MPB) and 98% mobile phase A (MPA) 
for 4min, MPB was then increased to 30% over 40min, raised to 40% MPB over 20min, 
increased to 95% over 10min, held for 2min, returned to 2% B in one minute and 
equilibrated for 15min.  MPA was composed of 98:2 (water/acetonitrile) with 0.2% FA 
and MPB was composed of 80:10:10 (acetonitrile/ isopropyl alcohol/water) with 0.2% FA. 
Analysis of the eluting peptides was performed using an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Scientific) operated in data dependent mode.  Survey scans were 





fill time of 50ms.  MS/MS scans of selected precursor ions were performed for a maximum 
of 3s or until the list was exhausted and dynamic exclusion was set to 45s.  Quadrupole 
isolation for MS/MS scans was set at 0.7 m/z followed by fragmentation in the ion trap 
with “Rapid” scan speed and an ion target value of 5e4 and maximum injection time of 
22ms using normalized collision energy of 28% from 200-1200 m/z.  The monoisotopic 
precursor selection was set to peptide and charge states of 1, greater than 5, or unknown 
were excluded.   
Data Analysis 
MS raw files were processed in MaxQuant software version 1.6.12  Peptides were 
searched using the Andromeda search engine against the human Uniprot FASTA database 
downloaded July 24th, 2019.  Cysteine carbamidomethylation was set as a fixed 
modification and N-terminal acetylation and methionine oxidation were set as variable 
modifications.  Searches were performed with a false discovery rate of 1% for both peptides 
and proteins using a target-decoy approach.  Peptide length was to at least 7 amino acids 
long and MS2 match tolerance was set to 0.5Da.  Enzyme specificity was set to trypsin and 
a maximum of 2 missed cleavages were allowed.  Protein data was extracted from the 
“proteinGroups.txt” file and differential quantitation was carried out using a generalized 
linear model as previously described (56). 
Gene Ontology Over Representation Analysis 
Gene ontology over representation analysis was preformed using WebGestalt 





method using the R package apcluster and gene sets passing FDR (Benjamimi-Hochberg 






Chapter 5: Conclusion 
In summary, this dissertation describes the application of several analytical and 
bioinformatics based tools to study EV mediated intercellular communication in exercise, 
exercise resistance in obesity, and EVs as biomarkers of disease biology in multiple 
myeloma. Fist, we developed and characterized a platform to profile and quantify the 
proteome of plasma derived EVs, termed SEC-MS. We demonstrate that this method is 
superior to the current gold standard UTC and can reproducibly measure the abundance of 
EV proteins over a large dynamic range. We then applied this method to study the release 
of EVs after endurance and resistance exercise and use cell line studies to identify tissue 
specific EV proteins.  
 
EVs are thought to mediate intercellular communication in several physiological 
and pathological states. Prior to determining the role of EVs obesity associated exercise 
resistance, the molecular alterations within muscle tissue at baseline and after exercise need 
to be extensively characterized. Therefore, we performed a multi-omics analysis of muscle 
biopsy samples to compare lean and obese individuals at baseline and in response to 
exercise. This study identified several important alterations in obese individuals. At 
baseline, we identified derangements in oxidative phosphorylation as well as deficits in 
protein translation, both of which have been previously characterized. We also identified 
novel alterations in phosphorylation and kinase activity, in which obese individuals had 
reduced activity of several important kinases.  We also identified unique response to 





Finally, multi-omics integration identified deficits in GSK3β signaling within obese 
individuals which will likely be the impetus for future studies of glycogen synthesis in 
obesity.  
Finally, we leveraged SEC-MS to investigate EVs as biomarkers of disease biology 
in MM. This study found upregulation of two interesting proteins in MM relative to 
MGUS. In MM, TFRC and CD40 are upregulated in SEVs and LEVs respectively. The 
upregulation of these proteins may be associated with conditions within the tumor micro-
environment, however, additional studies will be required to confirm these findings. 
Furthermore, many proteins are upregulated SEVs and LEVS in patients with standard 
cytogenetic risk relative. Functional enrichment analysis of these proteins suggests they 
are involved in immune function, which may indicate that high cytogenetic risk is 
associated with reduced adaptive immune function. Moreover, within LEVs we found 
CD40 to be upregulated in MM patients relative to MGUS, but only in patients with 
standard risk. In high risk MM patients, CD40 was undetectable, further indicating that 
high cytogenetic risk may be associated with impaired immune function.  
In concussion, these studies have made significant contributions to research in 
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